Exon-skipping oligomers and oligomer conjugates for muscular dystrophies

Antisense oligomers conjugated with a cell-penetrating peptide induce exon 53 skipping in the dystrophin gene to produce functional dystrophin, addressing the limitations of existing technologies in treating Duchenne muscular dystrophy by restoring protein production.

JP7579147B2Active Publication Date: 2024-11-07SAREPTA THERAPEUTICS INC
View PDF 41 Cites 0 Cited by

Patent Information

Application Number
JP2020568237
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-06-14
Filing Date
2019-06-13
Publication Date
2024-11-07
Estimated Expiration
2039-06-13

AI Technical Summary

Technical Problem

Current antisense oligomers are ineffective in upregulating native protein production or compensating for mutations that cause premature termination of translation, such as in Duchenne muscular dystrophy (DMD), as they either promote decay of target mRNA or block translation, which is not suitable for treating genetic diseases like DMD.

Method used

Development of antisense oligomers and oligomer conjugates that bind to the human dystrophin gene to induce exon 53 skipping, using a cell membrane-penetrating peptide (CPP) conjugated to an antisense oligomer to restore the reading frame and produce functional dystrophin protein.

Benefits of technology

The antisense oligomers and conjugates effectively induce exon skipping in the dystrophin gene, producing a truncated but functional dystrophin protein, thereby improving muscle function and treating DMD by increasing dystrophin production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579147000130
    Figure 0007579147000130
  • Figure 0007579147000131
    Figure 0007579147000131
  • Figure 0007579147000132
    Figure 0007579147000132
Patent Text Reader

Abstract

Antisense oligomers and antisense oligomer conjugates complementary to selected target sites in the human dystrophin gene for inducing exon 53 skipping are described.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Application No. 62 / 685,064, filed June 14, 2018. The entire teachings of the above applications are incorporated by reference in their entireties.

[0002] References to sequence listings submitted electronically via EFS-WEB The contents of the electronically submitted sequence listing (name: 8165_53_WO00_SL.txt, size: 62,579 bytes, created on May 29, 2019) filed concurrently with this specification are incorporated herein by reference in their entirety.

[0003] The present disclosure relates to novel antisense oligomers and antisense oligomer conjugates suitable for exon 53 skipping in the human dystrophin gene, and pharmaceutical compositions thereof. The present disclosure also provides methods for inducing exon 53 skipping using the novel antisense oligomers and antisense oligomer conjugates, methods for producing dystrophin in subjects with a mutation in the dystrophin gene suitable for exon 53 skipping, and methods for treating subjects with a mutation in the dystrophin gene suitable for exon 53 skipping. [Background technology]

[0004] Antisense technology has been developed using a variety of chemistries to affect gene expression at a variety of different levels (transcription, splicing, stability, translation). Most of the research has focused on the use of antisense compounds to correct or compensate for abnormal or disease-related genes in a wide range of indications. Antisense molecules can inhibit gene expression with specificity, and for this reason many research efforts on oligomers as modulators of gene expression have focused on inhibiting the expression of target genes or the function of cis-acting elements. Antisense oligomers are typically directed against RNA, either the sense strand (e.g., mRNA) or, in the case of some viral RNA targets, the minus strand. To achieve the desired effect of downregulating a specific gene, oligomers generally promote the decay of the target mRNA, block the translation of the mRNA, or block the function of a cis-acting RNA element, thereby effectively preventing either the de novo synthesis of the target protein or the replication of the viral RNA.

[0005] However, such techniques are not useful when the goal is to upregulate the production of a native protein or to compensate for mutations that induce premature termination of translation, such as nonsense or frameshift mutations. In these cases, the defective gene transcript should not be subject to targeted degradation or steric inhibition, and therefore the chemistry of the antisense oligomer should neither promote the decay of the target mRNA nor block translation.

[0006] In various genetic diseases, the effect of mutations on the final expression of genes can be regulated through the process of targeted exon skipping during the splicing process. The splicing process is directed by a complex multi-component mechanism that brings adjacent exon-intron junctions in pre-mRNA into close proximity and performs phosphodiester bond cleavage at the end of the intron, with the subsequent reconstitution of phosphodiester bonds between exons that are spliced ​​together. This complex and highly precise process is mediated by sequence motifs in pre-mRNA, which are relatively short semi-conserved RNA segments, and then various nuclear splicing factors involved in the splicing reaction bind to the sequence motifs. By changing the way the splicing machinery reads or recognizes the motifs involved in pre-mRNA processing, it is possible to create differentially spliced ​​mRNA molecules. It is recognized that the majority of human genes are alternatively spliced ​​during normal gene expression, but the mechanisms involved have not been identified. Bennett et al. (U.S. Patent No. 6,210,892) describe antisense regulation of wild-type cellular mRNA processing using antisense oligomer analogs that do not induce RNAse H-mediated cleavage of the target RNA. This finds utility in being able to generate alternatively spliced ​​mRNAs that lack specific exons (e.g., as described in Sazani, Kole, et al. 2007 for the generation of soluble TNF superfamily acceptors that lack exons encoding transmembrane domains).

[0007] When a normally functional protein is prematurely terminated due to a mutation therein, it has been shown that a means to restore some functional protein production by antisense technology is possible through intervention in the splicing process, and it has also been shown that when exons associated with disease-causing mutations can be specifically deleted from some genes, truncated protein products can sometimes be produced that have similar biological properties of the native protein or that have sufficient biological activity to ameliorate the disease caused by the exon-associated mutation (see, e.g., Sierakowska, Sambade et al. 1996; Wilton, Lloyd et al. 1999; van Deutekom, Bremmer-Bout et al. 2001; Lu, Mann et al. 2003; Aartsma-Rus, Janson et al. 2004). Kole et al. (U.S. Patent Nos. 5,627,274, 5,916,808, 5,976,879, and 5,665,593) disclose methods to counter aberrant splicing using modified antisense oligomer analogs that do not promote decay of the target pre-mRNA. Bennett et al. (U.S. Patent No. 6,210,892) similarly describe antisense regulation of wild-type cellular mRNA processing using antisense oligomer analogs that do not induce RNAse H-mediated cleavage of the target RNA.

[0008] The process of targeted exon skipping is likely to be particularly useful in long genes where many exons and introns exist, where there is redundancy in the genetic organization of exons, or where proteins can function without one or more specific exons. Efforts to redirect gene processing for the treatment of genetic diseases associated with truncations caused by mutations in various genes have focused on the use of antisense oligomers that (1) fully or partially overlap with elements involved in the splicing process, or (2) bind to pre-mRNA at a position close enough to the element to prevent the binding and function of splicing factors that normally mediate the specific splicing reaction that occurs at that element.

[0009] Duchenne muscular dystrophy (DMD) is caused by defective expression of the protein dystrophin. The gene that codes for the protein contains 79 exons that are spread over more than 2 million nucleotides of DNA. Any mutation in an exon, which changes the reading frame of the exon, introduces a stop codon, or is characterized by the movement of one or more exons completely out of frame or the duplication of one or more exons, can prevent the production of functional dystrophin and lead to DMD.

[0010] Mutations, typically deletions of one or more exons, have been shown to result in a less severe form of muscular dystrophy, Becker muscular dystrophy (BMD), if they result in the correct reading frame along the entire dystrophin transcript and thus premature termination of translation of the mRNA into protein. If the joining of upstream and downstream exons in the processing of the mutated dystrophin pre-mRNA maintains the correct reading frame of the gene, the result is an mRNA that codes for a protein with a short internal deletion that retains some activity, resulting in the Becker phenotype.

[0011] For many years, it has been known that the deletion of exon(s) that does not change the reading frame of dystrophin protein causes BMD phenotype, while the deletion of exon that causes frame shift causes DMD (Monaco, Bertelson et al. 1988). In general, dystrophin mutations, including point mutations and exon deletions that change the reading frame and thus interrupt proper protein translation, result in DMD. It should also be noted that some BMD and DMD patients have exon deletions that span multiple exons.

[0012] Modulation of mutant dystrophin pre-mRNA splicing using antisense oligoribonucleotides has been reported both in vitro and in vivo (see, for example, Matsuo, Masumura et al. 1991; Takeshima, Nishio et al. 1995; Pramono, Takeshima et al. 1996; Dunckley, Eperon et al. 1997; Dunckley, Manoharan et al. 1998; Wilton, Lloyd et al. 1999; Mann, Honeyman et al. 2002; Errington, Mann et al. 2003).

[0013] Antisense oligomers are specifically designed to target specific regions of pre-mRNA, typically exons, to induce skipping of DMD gene mutations, thereby restoring these out-of-frame mutations in frame and allowing the production of an internally truncated but functional dystrophin protein. Such antisense oligomers are known to target entirely within an exon (so-called exon internal sequences) or at splice donor or splice acceptor junctions crossing from an exon to a portion of an intron.

[0014] The discovery and development of such antisense oligomers against DMD has been an area of ​​past research.These developments include: (1) the University of Western Australia and Sarepta Therapeutics (the assignee of this application): WO2006 / 000057, WO2010 / 048586, WO2011 / 057350, WO2014 / 100714, WO2014 / 153240, WO2014 / 153220; (2) Academisch Ziekenhuis Leiden / Prosensa Technologies (now BioMarin Pharmaceutical): WO02 / 24906, WO2004 / 083432, WO2004 / 083446, WO2006 / 112705, WO2007 / 133105, WO2009 / 139630 , WO2009 / 054725, WO2010 / 050801, WO2010 / 050802, WO2010 / 123369, WO2013 / 112053, WO2014 / 007620, (3) Carolinas Medical Center:WO2012 / 109296, (4)Royal Holloway: patents and applications claiming the benefit of and including US 61 / 096,073 and 61 / 164,978, e.g., US 8,084,601 and US 2017-0204413; (4) JCR Pharmaceuticals and Matsuo: patents and applications claiming the benefit of US 6,653,466; JP 2000-125448, e.g., US 6,653,467; JP 2000-256547, e.g., US 6,727,355; WO 2004 / 048570; (5) Nippon This includes developments from Shinyaku: WO2012 / 029986, WO2013 / 100190, WO2015 / 137409, WO2015 / 194520, and (6) Association Institut de Myologie / Universite Pierre et Marie Curie / Universitat Bern / Centre national de la Recherche Scientifique / Synthena AG: WO2010 / 115993, WO2013 / 053928.

[0015] The discovery and development of antisense oligomers conjugated to cell membrane-permeable peptides for DMD has also been an area of ​​research (PCT Publication No. WO2010 / 048586; Wu, B. et al., The American Journal of Pathology, Vol. 181(2): 392-400, 2012; Wu, R. et al., Nucleic Acids Research, Vol. 35(15): 5182-5191, 2007; Mulders, S. et al., 19 thInternational Congress of the World Muscle Society,Poster Presentation Berlin,October 2014, Bestas,B.et al.,The Journal of Clinical Investigation,doi:10.1172 / JCI76175,2014, Jearawiriyapaisarn,N.et al.,Molecular Therapy,Vol.16(9):1624-1629,2008, Jearawiriyapaisarn,N.et al.,Cardiovascular Research,Vol.85:444-453,2010,Moulton,HMet al.,Biochemical Society Transactions,Vol.35(4):826-828,2007,Yin,H.et al.,Molecular Therapy,Vol.19(7):1295-1303,2011, Abes,R.et al., J. Pept. Sci., Vol. 14:455-460, 2008, Lebleu, B. et al., Advanced Drug Delivery Reviews, Vol. 60: 517-529, 2008, McClorey, G. et al., Gene Therapy, Vol. 13: 1373-1381, 2006, Alter, J. et al., Nature Medicine, Vol. 12(2):175-177, 2006, and Youngblood, D. et al., American Chemical Society, Bioconjugate Chem., 2007, 18(1), pp 50-60). Transport moieties such as cell membrane penetrating peptides (CPPs), eg, arginine-rich peptides, can be effective in enhancing intracellular penetration of antisense oligomers conjugated to the CPPs. Despite these efforts, there remains a need for improved antisense oligomers that target exon 53 and corresponding pharmaceutical compositions that may be useful in therapeutic methods for producing dystrophin and treating DMD. [Prior art documents] [Patent documents]

[0016] [Patent Document 1] U.S. Patent No. 6,210,892 [Patent Document 2] U.S. Pat. No. 5,627,274 [Patent Document 3] U.S. Pat. No. 5,916,808 [Patent Document 4] U.S. Pat. No. 5,976,879 [Patent Document 5] U.S. Pat. No. 5,665,593 [Patent Document 6] U.S. Patent No. 6,210,892 [Patent Document 7] International Publication No. 2006 / 000057 [Patent Document 8] International Publication No. 2010 / 048586 [Patent Document 9] International Publication No. 2011 / 057350 [Patent Document 10] International Publication No. 2014 / 100714 [Patent Document 11] International Publication No. 2014 / 153240 [Patent Document 12] International Publication No. 2014 / 153220 [Patent Document 13] International Publication No. 2002 / 024906 [Patent Document 14] International Publication No. 2004 / 083432 [Patent Document 15] International Publication No. 2004 / 083446 [Patent Document 16] International Publication No. 2006 / 112705 [Patent Document 17] International Publication No. 2007 / 133105 [Patent Document 18] International Publication No. 2009 / 139630 [Patent Document 19] International Publication No. 2009 / 054725 [Patent Document 20] International Publication No. 2010 / 050801 [Patent Document 21] International Publication No. 2010 / 050802 [Patent Document 22] International Publication No. 2010 / 123369 [Patent Document 23] International Publication No. 2013 / 112053 [Patent Document 24] International Publication No. 2014 / 007620 [Patent Document 25] International Publication No. 2012 / 109296 [Patent Document 26] U.S. Pat. No. 8,084,601 [Patent Document 27] US Patent Application Publication No. 2017 / 0204413 [Patent Document 28] U.S. Patent No. 6,653,466 [Patent Document 29] JP 2000-125448 A [Patent Document 30] U.S. Pat. No. 6,653,467 [Patent Document 31] JP 2000-256547 A [Patent Document 32] U.S. Patent No. 6,727,355 [Patent Document 33] International Publication No. 2004 / 048570 [Patent Document 34] International Publication No. 2012 / 029986 [Patent Document 35] International Publication No. 2013 / 100190 [Patent Document 36] International Publication No. 2015 / 137409 [Patent Document 37] International Publication No. 2015 / 194520

Patent document 38

Patent document 39

Non-licensed literature

[0017]

Non-licensed literature 1

Non-licensed Document 2

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

[0018] The present disclosure provides antisense oligomers and antisense oligomer conjugates comprising an antisense oligomer moiety conjugated to a CPP. In one embodiment, the present disclosure provides an antisense oligomer of 18-25 subunits in length capable of binding to a selected target to induce exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases complementary to the exon 53 target region of the dystrophin pre-mRNA designated as an annealing site.

[0019] In some embodiments, the present disclosure provides an antisense oligomer 25 subunits in length capable of binding to a selected target to induce exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases that is complementary to an exon 53 target region of a dystrophin pre-mRNA designated as an annealing site.

[0020] In another aspect, the present disclosure provides: an antisense oligomer of 18 to 25 subunits in length capable of binding to a selected target for inducing exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases complementary to an exon 53 target region of the dystrophin pre-mRNA designated as an annealing site; and a cell membrane penetrating peptide (CPP) conjugated to the antisense oligomer by a linker moiety.

[0021] In some embodiments, the annealing site is selected from H53A(+23+47), H53A(+39+62), H53A(+36+69), and H53A(+45+62).

[0022] In various embodiments, the present disclosure provides a method for producing a pharmaceutical composition comprising: an antisense oligomer of 25 subunits in length capable of binding to a selected target for inducing exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases complementary to an exon 53 target region of the dystrophin pre-mRNA designated as an annealing site; and a cell membrane penetrating peptide (CPP) conjugated to the antisense oligomer by a linker moiety.

[0023] In some embodiments, the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0024] In some embodiments, the annealing site is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30- 06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A( -9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D( +24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-0) 9), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0025] In some embodiments, the annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), ), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H 53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H5 H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0026] In some embodiments, the antisense oligomer is of 20-23 subunits. In some embodiments, the bases of the antisense oligomer are linked to morpholino ring structures that are joined by phosphorus-containing intersubunit linkages connecting the morpholino nitrogen of one ring structure to the 5' exocyclic carbon of an adjacent ring structure. In certain embodiments, the cell membrane penetrating peptide is comprised of 6 arginine units ("R 6 ") (SEQ ID NO: 135), and the linker moiety is glycine. In some embodiments, the antisense oligomer comprises a sequence of bases selected from SEQ ID NOs: 1-65. In various embodiments, the antisense oligomer comprises a sequence of bases selected from SEQ ID NOs: 70-134.

[0027] In various embodiments, the present disclosure provides an antisense oligomer conjugate, which may be according to formula (I): [ka] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase that together form a targeting sequence, T, [ka] is a moiety selected from R 1 But, C 1 ~C 6 alkyl, or a pharma- ceutically acceptable salt thereof.

[0028] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA, where the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0029] In some embodiments, the targeting sequence is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A (-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+0) 8), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A( -8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+ 23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), is complementary to an exon 53 annealing site selected from the group consisting of H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0030] In some embodiments, the targeting sequence is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-2 0+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15 +10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+1 5), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53 A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D( and is complementary to an exon 53 annealing site selected from the group consisting of H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0031] In another aspect, the present disclosure provides an antisense oligomer conjugate of formula (IV): [ka] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase that together form a targeting sequence, T, [ka] is a moiety selected from R 1 But, C 1 ~C 6 is alkyl, R 2 is selected from H or acetyl, or a pharma- ceutically acceptable salt thereof.

[0032] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA, where the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0033] In some embodiments, the targeting sequence is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A (-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+0) 8), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A( -8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+ 23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), is complementary to an exon 53 annealing site selected from the group consisting of H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0034] In some embodiments, the targeting sequence is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-2 0+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15 +10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+1 5), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53 A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D( and is complementary to an exon 53 annealing site selected from the group consisting of H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0035] In another aspect, the present disclosure provides a pharmaceutical composition comprising an antisense oligomer conjugate of the present disclosure and a pharma- ceutically acceptable carrier. In some embodiments, the pharma-ceutically acceptable carrier is saline containing a phosphate buffer. In another aspect, the present disclosure provides a pharmaceutical composition comprising an antisense oligomer of the present disclosure and a pharma-ceutically acceptable carrier. In some embodiments, the pharma-ceutically acceptable carrier is saline containing a phosphate buffer.

[0036] In another embodiment, the present disclosure provides a method for treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene that is amenable to exon 53 skipping, the method comprising administering to the subject an antisense oligomer conjugate of the present disclosure. The present disclosure also addresses the use of an antisense oligomer conjugate of the present disclosure for the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene that is amenable to exon 53 skipping.

[0037] In another embodiment, the present disclosure provides a method for treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene that is amenable to exon 53 skipping, the method comprising administering to the subject an antisense oligomer of the present disclosure. The present disclosure also addresses the use of an antisense oligomer of the present disclosure for the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene that is amenable to exon 53 skipping.

[0038] In another embodiment, the present disclosure provides a method of restoring the mRNA reading frame to induce dystrophin production in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering to the subject an antisense oligomer conjugate of the present disclosure.In another embodiment, the present disclosure provides a method of excluding exon 53 from a dystrophin pre-mRNA during mRNA processing in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering to the subject an antisense oligomer conjugate of the present disclosure.In another embodiment, the present disclosure provides a method of binding exon 53 of a dystrophin pre-mRNA in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering to the subject an antisense oligomer conjugate of the present disclosure.

[0039] In another embodiment, the present disclosure provides a method of restoring the mRNA reading frame to induce dystrophin production in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering an antisense oligomer of the present disclosure to the subject.In another embodiment, the present disclosure provides a method of excluding exon 53 from a dystrophin pre-mRNA during mRNA processing in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering an antisense oligomer of the present disclosure to the subject.In another embodiment, the present disclosure provides a method of binding exon 53 of a dystrophin pre-mRNA in a subject having a mutation in the dystrophin gene that is suitable for exon 53 skipping, the method comprising administering an antisense oligomer of the present disclosure to the subject.

[0040] In another aspect, the present disclosure provides the antisense oligomer conjugate of the present disclosure herein for use in therapy.In certain embodiments, the present disclosure provides the antisense oligomer conjugate of the present disclosure for use in the treatment of Duchenne muscular dystrophy.In certain embodiments, the present disclosure provides the antisense oligomer conjugate of the present disclosure for use in the manufacture of a medicament for use in therapy.In certain embodiments, the present disclosure provides the antisense oligomer conjugate of the present disclosure for use in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy.

[0041] In another aspect, the present disclosure provides the antisense oligomer of the present disclosure herein for use in therapy.In certain embodiments, the present disclosure provides the antisense oligomer of the present disclosure for use in the treatment of Duchenne muscular dystrophy.In certain embodiments, the present disclosure provides the antisense oligomer of the present disclosure for use in the manufacture of a medicament for use in therapy.In certain embodiments, the present disclosure provides the antisense oligomer of the present disclosure for use in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy.

[0042] In another embodiment, the present disclosure also provides a kit for treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene amenable to exon 53 skipping, the kit comprising at least an antisense oligomer conjugate of the present disclosure packaged in a suitable container and instructions for its use.

[0043] In another aspect, the disclosure also provides a kit for treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, the subject having a mutation in the dystrophin gene amenable to exon 53 skipping, the kit comprising at least an antisense oligomer of the disclosure packaged in a suitable container and instructions for its use.

[0044] These and other objects and features will be more fully understood when the following detailed description of the present disclosure is read in conjunction with the drawings. In certain embodiments, for example, the following items are provided: (Item 1) An antisense oligomeric conjugate of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase that together form a targeting sequence, T, [ka] is selected from R 1 But, C 1 ~C 6 is alkyl, The targeting sequence is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A(-25-01), H53A(-24 +01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A (-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H53A(-7+18), H53A (-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+ 21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53 16. An antisense oligomer conjugate which is complementary to an exon 53 annealing site in a dystrophin pre-mRNA selected from the group consisting of H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25). (Item 2) The annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H5 3A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53 A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A 2. The antisense oligomer conjugate of claim 1, selected from the group consisting of H53D(+17-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24). (Item 3) 2. The antisense oligomer conjugate according to item 1, wherein the targeting sequence is selected from the group consisting of SEQ ID NOs: 70 to 134. (Item 4) 3. The antisense oligomer conjugate according to item 2, wherein the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83, 85-100, 102-104, 108-115, 117, 118, 121, 122, 127, and 133. (Item 5) The antisense oligomer conjugate of item 1, wherein each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I). (Item 6) An antisense oligomeric conjugate of formula (III): [ka] or a pharma- ceutically acceptable salt thereof, wherein each Nu is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A(-25-01), H53A(-25-02), H53A(-25-03), H53A(-25-04), H53A(-25-05), H53A(-25-06), H53A(-25-07), H53A(-25-09), H53A(-25-10), H53A(-25-11), H53A(-25-12), H53A(-25-13), H53A(-25-14), H53A(-25-15), H53A(-25-16), H53A(-25-17), H53A(-25-19), H53A(-25-20), H53A(-25-21), H53A(-25-22), H53A(-25-23), H53A(-25-24), H53A(-25-25), H53A(-25-31), H53A(-25-16), H53A(-25-19), 3A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+ 05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53 A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+1) 4), H53A(-10+15), H53A(-9+16), H53A(-8+17), H53A(-7+18), H53A(-6+ 19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1 +24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H5 3D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16- 09), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53 23. An antisense oligomer conjugate, comprising nucleobases which together form a targeting sequence which is complementary to an exon 53 annealing site in a dystrophin pre-mRNA selected from the group consisting of H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25). (Item 7) The annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H5 3A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53 A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A 7. The antisense oligomer conjugate of item 6, selected from the group consisting of H53D(+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24). (Item 8) 7. The antisense oligomer conjugate according to item 6, wherein the targeting sequence is selected from the group consisting of SEQ ID NOs: 70 to 134. (Item 9) 8. The antisense oligomer conjugate according to item 7, wherein the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83, 85-100, 102-104, 108-115, 117, 118, 121, 122, 127, and 133. (Item 10) An antisense oligomer of formula (IV):

change

change

change

change

[0045] [Figure 1] Sections of normal dystrophin pre-mRNA and mature mRNA are shown. [Diagram 2] Shown is a section of abnormal dystrophin pre-mRNA (an example of DMD) and the resulting non-functional, unstable dystrophin. [Diagram 3] FIG. 1 shows eteplirsen engineered to skip exon 51, restoring "in-frame" reading of the pre-mRNA. [Figure 4A] Representative images of Western blot analysis are provided measuring dystrophin protein in the quadriceps muscle of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different time points [day 7 (5A), day 30 (5B), day 60 (5C), and day 90 (5D)]. [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 4D] Same as above. [Diagram 5] (FIG. 5A) Line graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the quadriceps of mdx mice over a 90-day post-injection period as determined by Western blot analysis. (FIG. 5B) Line graph showing the percentage of exon 23 skipping induced by PMO (PMO4225) or PPMO (PPMO4225) in the quadriceps of mdx mice over a 90-day post-injection period as determined by RT-PCR. [Figure 6A] Representative images of Western blot analysis are provided measuring dystrophin protein in the diaphragm of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different time points [day 7 (7A), day 30 (7B), day 60 (7C), and day 90 (7D)]. [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 7] (FIG. 7A) Line graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the diaphragm of mdx mice over a 90-day period after injection as determined by Western blot analysis. (FIG. 7B) Line graph showing the percentage of exon 23 skipping induced by PMO (PMO4225) or PPMO (PPMO4225) in the diaphragm of mdx mice over a 90-day period after injection as determined by RT-PCR. [Figure 8A] Representative images of Western blot analysis are provided measuring dystrophin protein in the hearts of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different time points [day 7 (9A), day 30 (9B), day 60 (9C), and day 90 (9D)]. [Figure 8B] Same as above. [Figure 8C] Same as above. [Figure 8D] Same as above. [Figure 9] (FIG. 9A) Line graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the hearts of mdx mice over a 90-day period after injection as determined by Western blot analysis. (FIG. 9B) Line graph showing the percentage of exon 23 skipping induced by PMO (PMO4225) or PPMO (PPMO4225) in the hearts of mdx mice over a 90-day period after injection as determined by RT-PCR. [Figure 10] 1 provides immunohistochemical analysis showing dystrophin in the left quadriceps muscle of mdx mice induced by PMO (PMO4225) or PPMO (PPMO4225). [Figure 11A] Representative images of Western blot analysis measuring dystrophin protein in the hearts of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 11B] Same as above. [Figure 12] 1 is a bar graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the hearts of mdx mice, as determined by Western blot analysis, 30 days after injection at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 13A] Representative images of Western blot analysis measuring dystrophin protein in the diaphragm of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 13B] Same as above. [Figure 14]1 is a bar graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the diaphragm of mdx mice, as determined by Western blot analysis, 30 days after injection at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 15A] Representative images of Western blot analysis measuring dystrophin protein in the quadriceps muscle of mdx mice treated with PMO (PMO4225) or PPMO (PPMO4225) at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 15B] Same as above. [Figure 16] 1 is a bar graph showing the percentage of wild-type dystrophin induced by PMO (PMO4225) or PPMO (PPMO4225) in the quadriceps of mdx mice, as determined by Western blot analysis, 30 days after injection at different doses: 40 mg / kg, 80 mg / kg, and 120 mg / kg. [Figure 17] 1 provides immunohistochemistry analysis showing dystrophin and laminin in mdx mouse diaphragm and heart induced by PPMO (PPMO4225) compared to saline in mdx and wild type mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] The embodiments of the present disclosure generally relate to improved antisense oligomers and antisense oligomer conjugates, and their use methods, which are specifically designed to induce exon skipping in human dystrophin gene.Dystrophin plays an important role in muscle function, and various muscle-related diseases are characterized by the mutant form of this gene.Therefore, in certain embodiments, the improved antisense oligomers and antisense oligomer conjugates described herein induce exon skipping in the mutant form of human dystrophin gene, such as the mutant dystrophin gene found in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

[0047] Due to the abnormal mRNA splicing events caused by mutation, these mutant human dystrophin genes either express defective dystrophin protein or do not express measurable dystrophin at all, which is the condition that causes various forms of muscular dystrophy.To treat this condition, the antisense oligomer and antisense oligomer conjugate of the present disclosure hybridize to the selected region of the pre-processed mRNA of mutant human dystrophin gene, and induce exon skipping and differential splicing in otherwise abnormally spliced ​​dystrophin mRNA, thereby allowing muscle cells to produce the mRNA transcript that codes for functional dystrophin protein.In certain embodiments, the resulting dystrophin protein is not necessarily the "wild type" form of dystrophin, but rather a truncated but functional form of dystrophin.

[0048] By increasing the levels of functional dystrophin protein in muscle cells, these and related embodiments are useful for the prevention and treatment of muscular dystrophies, particularly forms of muscular dystrophies such as DMD and BMD, which are characterized by defective expression of dystrophin protein due to aberrant mRNA splicing. Certain antisense oligomers and antisense oligomer conjugates described herein further provide improved dystrophin-exon specific targeting over other oligomers, thereby providing significant and practical advantages over alternative methods of treating related forms of muscular dystrophies.

[0049] Thus, the present disclosure: an antisense oligomer of 18 to 25 subunits in length capable of binding to a selected target for inducing exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases complementary to an exon 53 target region of the dystrophin pre-mRNA designated as an annealing site; and a cell membrane penetrating peptide (CPP) conjugated to the antisense oligomer via a linker moiety.

[0050] In some embodiments, the annealing site is selected from H53A(+23+47), H53A(+39+62), H53A(+36+69), and H53A(+45+62).

[0051] Thus, the present disclosure: an antisense oligomer of 25 subunits in length capable of binding to a selected target for inducing exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases complementary to an exon 53 target region of the dystrophin pre-mRNA designated as an annealing site; and a cell membrane penetrating peptide (CPP) conjugated to the antisense oligomer via a linker moiety.

[0052] The present disclosure also relates to an antisense oligomer of 25 subunits in length capable of binding to a selected target to induce exon skipping in the human dystrophin gene, the antisense oligomer comprising a sequence of bases that is complementary to an exon 53 target region of a dystrophin pre-mRNA designated as an annealing site.

[0053] In some embodiments, the annealing site is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30- 06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A( -9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D( +24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-0) 9), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0054] In some embodiments, the annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), ), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H 53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H5 H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0055] In some embodiments, the bases of the antisense oligomer are linked to morpholino ring structures that are joined by phosphorus-containing intersubunit linkages that connect the morpholino nitrogen of one ring structure to the 5' exocyclic carbon of an adjacent ring structure. 6 (SEQ ID NO: 135), and the linker moiety is glycine.

[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.Any method and material similar or equivalent to those described herein can be used in the practice or testing of this disclosure, but preferred methods and materials are described.For the purpose of this disclosure, the following terms are defined below.

[0057] I. definition "About" means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by up to 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0058] As used herein, the term "alkyl" refers to a saturated straight chain or branched hydrocarbon, unless otherwise specified. In certain embodiments, an alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, an alkyl group is a group having 1 to 10 carbon atoms, i.e., C 1 ~C 10 In certain embodiments, the alkyl group is a group having 1 to 6 carbon atoms, i.e., C 1 ~C 6 In certain embodiments, the alkyl group is methyl, CF 3 , CCl 3 , CFCl 2 , C.F. 2 Cl, ethyl, CH 2 CF 3 , C.F. 2 CF 3, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. This term includes both substituted and unsubstituted alkyl groups, including halogenated alkyl groups. In certain embodiments, the alkyl group is a fluorinated alkyl group. Non-limiting examples of moieties that the alkyl group can be substituted with are selected from the group consisting of halogen (fluoro, chloro, bromo, or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected or protected as required, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, which is incorporated herein by reference.

[0059] "Suitable for exon 53 skipping", as used herein with respect to a subject or patient, is intended to include subjects and patients with one or more mutations in the dystrophin gene that, without skipping of exon 53 of the dystrophin pre-mRNA, would render the reading frame out of frame, thereby preventing translation of the pre-mRNA and rendering the subject or patient unable to produce functional or semi-functional dystrophin. Examples of mutations in the dystrophin gene that are suitable for exon 53 skipping include, for example, deletions of exons 42-52, exons 45-52, exons 47-52, exons 48-52, exons 49-52, exons 50-52, or exon 52. It is well within the skill of one in the art to determine whether a patient has a mutation in the dystrophin gene that is amenable to exon skipping (see, e.g., Aartsma-Rus et al. (2009) Hum Mutat. 30:293-299; Gurvich et al., Hum Mutat. 2009;30(4)633-640; and Fletcher et al. (2010) Molecular Therapy 18(6)1218-1223).

[0060] As used herein, the term "oligomer" refers to a sequence of subunits linked by intersubunit linkages. In certain instances, the term "oligomer" is used in connection with "antisense oligomers." For "antisense oligomers," each subunit consists of (i) a ribose sugar or derivative thereof, and (ii) a nucleic acid base attached thereto, whereby the order of base-pairing moieties forms a base sequence that is complementary to a target sequence in a nucleic acid (typically RNA) by Watson-Crick base pairing to form a nucleic acid:oligomer heteroduplex within the target sequence, provided that either the subunit, the intersubunit linkage, or both are not naturally occurring. In certain embodiments, the antisense oligomer is a PMO. In other embodiments, the antisense oligomer is a 2'-O-methyl phosphorothioate. In other embodiments, the antisense oligomer of the present disclosure is a peptide nucleic acid (PNA), a locked nucleic acid (LNA), or a bridged nucleic acid (BNA), such as a 2'-O,4'-C-ethylene bridged nucleic acid (ENA). Additional exemplary embodiments are described herein.

[0061] The terms "complementary" and "complementarity" refer to two or more oligomers (i.e., each containing a nucleobase sequence) that are related to each other by Watson-Crick base pairing rules. For example, the nucleobase sequence "TGA(5'→3')" is complementary to the nucleobase sequence "ACT(3'→5')". Complementarity may be "partial", where less than all of the nucleobases of a given nucleobase sequence are matched to another nucleobase sequence according to the base pairing rules. For example, in some embodiments, the complementarity between a given nucleobase sequence and another nucleobase sequence may be about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. Or, continuing the example, there may be "complete" or "perfect" (100%) complementarity between a given nucleobase sequence and another nucleobase sequence. The degree of complementarity between nucleobase sequences has a significant effect on the efficiency and strength of hybridization between the sequences.

[0062] The terms "effective amount" and "therapeutically effective amount" are used interchangeably herein and refer to the amount of a therapeutic compound, such as an antisense oligomer, administered to a mammalian subject, either as a single dose or as part of a series of doses, that is effective to produce a desired therapeutic effect.For antisense oligomers, this effect is typically produced by inhibiting the translation or natural splice processing of a selected target sequence, or by producing a clinically significant amount of dystrophin (statistical significance).

[0063] In some embodiments, the effective amount is at least 10 mg / kg or at least 20 mg / kg of a composition comprising an antisense oligomer over a period of time to treat a subject. In some embodiments, the effective amount is at least 20 mg / kg of a composition comprising an antisense oligomer to increase the number of dystrophin-positive fibers in a subject to at least 20% of normal. In certain embodiments, the effective amount is at least 10 mg / kg or at least 20 mg / kg of a composition comprising an antisense oligomer to stabilize, maintain, or improve walking distance, for example, from a 20% deficit in the 6MWT, in a patient compared to a healthy counterpart. In various embodiments, the effective amount is at least 10 mg / kg to about 30 mg / kg, at least 20 mg / kg to about 30 mg / kg, about 25 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 50 mg / kg. In some embodiments, the effective amount is about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, or about 50 mg / kg. In another embodiment, the effective amount is at least about 10 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, or about 30 mg / kg to about 50 mg / kg for at least 24 weeks, at least 36 weeks, or at least 48 weeks, thereby increasing the number of dystrophin-positive fibers in the subject to at least 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% of normal, and stabilizing or improving walking distance in the patient, e.g., from a 20% deficit in the 6MWT, compared to a healthy counterpart. In some embodiments, the treatment increases the number of dystrophin-positive fibers in the patient to 20-60% or 30-50% of normal.

[0064] "Enhance" or "enhancing", or "increase" or "increasing", or "stimulate" or "stimulating" generally refers to the ability of any of the above antisense oligomers or antisense oligomer conjugates or pharmaceutical compositions to produce or cause a greater physiological response (i.e., downstream effect) in a cell or subject compared to the response caused by either no antisense oligomer, no antisense oligomer conjugate, or a control compound. A greater physiological response can include an increase in the expression of a functional form of dystrophin protein, or an increase in dystrophin-related biological activity in muscle tissue, among other responses that are apparent from the understanding in the art and the description herein. Increases in muscle function may also be measured, including increases or improvements in muscle function by up to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. The percentage of muscle fibers expressing functional dystrophin may also be measured, including an increase in dystrophin expression of about 1%, 2%, 5%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of muscle fibers. For example, it has been shown that an improvement in muscle function of about 40% can occur when 25-30% of fibers express dystrophin (see, e.g., DelloRusso et al, Proc Natl Acad Sci USA 99:12979-12984, 2002).An "increased" or "enhanced" amount is typically a "statistically significant" amount and can include an increase that is 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50-fold or more (e.g., 500, 1000-fold, including all integers and decimals therebetween and greater than 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.) over the amount produced by the absence of agent (no antisense oligomer or no antisense oligomer conjugate) or a control compound.

[0065] As used herein, terms such as "function" and "functionality" refer to biological, enzymatic, or therapeutic functions.

[0066] "Functional" dystrophin protein generally refers to a dystrophin protein that has sufficient biological activity to reduce the progressive degradation of muscle tissue otherwise characteristic of muscular dystrophy, typically compared to the "altered" or "missing" forms of dystrophin protein present in a particular subject with DMD or BMD.In certain embodiments, functional dystrophin protein can have about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% (including all integers therebetween) of the in vitro or in vivo biological activity of wild-type dystrophin, as measured according to conventional techniques in the art.As an example, dystrophin-related activity in in vitro muscle culture can be measured according to myotube size, myofibril organization (or disintegration), contractile activity, and spontaneous clustering of acetylcholine acceptors (see, for example, Brown et al., Journal of Cell Science.112:209-216,1999). Animal models are also valuable resources for studying disease pathogenesis and provide a means to test dystrophin-related activity.Two of the most widely used animal models for DMD research are mdx mice and golden retriever muscular dystrophy (GRMD) dogs, both of which are dystrophin-negative (see, for example, Collins & Morgan, Int J Exp Pathol 84:165-172, 2003).These and other animal models can be used to measure the functional activity of various dystrophin proteins.Includes truncated dystrophin, such as the form produced after administration of certain exon skipping antisense oligomers or antisense oligomer conjugates of the present disclosure.

[0067] The term "mismatch" (singular or plural) refers to one or more nucleobases (whether contiguous or separated) in an oligomer nucleobase sequence that do not match the target pre-mRNA according to base pairing rules. While perfect complementarity is often desired, some embodiments may include one or more, preferably 6, 5, 4, 3, 2, or 1 mismatches to the target pre-mRNA. Variations at any position within the oligomer are included. In certain embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure includes variations in nucleobase sequence near the internal terminal variations, when present, typically within about 6, 5, 4, 3, 2, or 1 subunits of the 5' and / or 3' end.

[0068] The terms "morpholino," "morpholino oligomer," and "PMO" have the following general structure: [ka] and as described in Figure 2 of Summerton, J., et al., Antisense & Nucleic Acid Drug Development, 7:187-195 (1997). The morpholino described herein includes all stereoisomers and tautomers of the above general structure. The synthesis, structure and binding properties of morpholino oligomers are described in detail in U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, 5,506,337, 8,076,476 and 8,299,206, all of which are incorporated herein by reference.

[0069] In certain embodiments, the morpholinos are conjugated to a "tail" moiety at the 5' or 3' end of the oligomer to enhance its stability and / or solubility. Exemplary tails include: [ka] Includes.

[0070] Of the exemplary tail moieties above, "TEG" or "EG3" refers to the following tail moieties: [ka]

[0071] Of the exemplary tail moieties above, "GT" refers to the following tail moieties: [ka]

[0072] As used herein, "-GR 6 " (SEQ ID NO: 136) and "-GR 6 The terms "R-Ac" (SEQ ID NO: 136) are used interchangeably to refer to a peptide moiety conjugated to an antisense oligomer of the disclosure. In various embodiments, "G" is linked to "R-Ac" by an amide bond. 6 " (SEQ ID NO: 135), and each "R" represents an arginine residue conjugated together by an amide bond, thereby forming "R 6 " (SEQ ID NO: 135) refers to six arginine residues (SEQ ID NO: 135) conjugated together by amide bonds. The arginine residues can have any configuration, for example, the arginine residues can be L-arginine residues, D-arginine residues, or a mixture of D-arginine residues and L-arginine residues. In certain embodiments, "-GR 6 " (SEQ ID NO: 136) or "-GR 6 In some embodiments, "-GR -Ac" (SEQ ID NO: 136) is conjugated to the morpholine ring nitrogen of the 3'-most morpholino subunit of a PMO antisense oligomer of the disclosure. 6 " (SEQ ID NO: 136) or "-GR 6-Ac" (SEQ ID NO: 136) is conjugated to the 3' end of the antisense oligomer of the disclosure and has the following formula: [ka]

[0073] The terms "nucleobase" (Nu), "base-pairing moiety," or "base" are used interchangeably to refer to the purine or pyrimidine bases found in naturally occurring or "natural" DNA or RNA (e.g., uracil, thymine, adenine, cytosine, and guanine), as well as analogs of these naturally occurring purines and pyrimidines. These analogs can confer improved properties, such as binding affinity, to oligomers. Exemplary analogs include hypoxanthine (the base component of inosine), 2,6-diaminopurine, 5-methylcytosine, C5-propynyl-modified pyrimidines, 10-(9-(aminoethoxy)phenoxazinyl) (G-clamp), and the like.

[0074] Further examples of base pairing moieties include, but are not limited to, uracil, thymine, adenine, cytosine, guanine, and hypoxanthine (inosine) (with their respective amino groups protected by acyl protecting groups), pyrimidine analogs such as 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pseudoisocytosine and pseudouracil, and other modified nucleobases such as 8-substituted purines, xanthines, or hypoxanthines (the latter two are natural decomposition products). Modified nucleobases disclosed in Chiu and Rana, RNA, 2003, 9, 1034-1048; Limbach et al. Nucleic Acids Research, 1994, 22, 2183-2196, and Revankar and Rao, Comprehensive Natural Products Chemistry, vol. 7, 313, the contents of which are incorporated herein by reference, are also contemplated.

[0075] Further examples of base pairing moieties include, but are not limited to, extended size nucleobases with one or more additional benzene rings. Nucleobase replacements described in the Glen Research catalog (www.glenresearch.com), Krueger AT et al., Acc. Chem. Res., 2007, 40, 141-150, Kool, ET, Acc. Chem. Res., 2002, 35, 936-943, Benner SA, et al., Nat. Rev. Genet., 2005, 6, 553-543, Romesberg, FE, et al., Curr. Opin. Chem. Biol., 2003, 7, 723-733, and Hirao, I., Curr. Opin. Chem. Biol., 2006, 10, 622-627, the contents of which are incorporated herein by reference, are contemplated as being useful in the antisense oligomers or antisense oligomer conjugates described herein. Examples of extended size nucleobases include those shown below, as well as tautomers thereof. [ka]

[0076] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0077] As used herein, a set of brackets used within a structural formula indicates that the structural feature between the brackets is repeated. In some embodiments, the brackets used may be "[" and "]", and in certain embodiments, the brackets used to indicate a repeating structural feature may be "(" and ")". In some embodiments, the number of repeating iterations of the structural feature between the brackets is the number shown outside the brackets, e.g., 2, 3, 4, 5, 6, 7, etc. In various embodiments, the number of repeating iterations of the structural feature between the brackets is indicated by a variable shown outside the brackets, such as "Z".

[0078] As used herein, a straight or squiggly bond drawn to a chiral carbon or phosphorus atom in a structural formula indicates that the stereochemistry of the chiral carbon or phosphorus is undefined and is intended to include all forms of the chiral center. Examples of such diagrams are shown below. [ka]

[0079] The phrase "pharmacologically acceptable" means that a substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the subject being treated.

[0080] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or any type of formulation auxiliary. Some examples of materials that can serve as pharmaceutically acceptable carriers include, according to the formulator's judgment, sugars such as lactose, glucose, sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, oleic acid ... leaven oil, corn oil, and soybean oil; glycols, such as propylene glycol esters, for example, ethyl oleate and ethyl laurate; agar; buffers, for example, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free distilled water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffers; non-toxic compatible lubricants, for example, sodium lauryl sulfate and magnesium stearate; colorants; release agents; coating agents; sweetening agents; flavoring agents; fragrances; preservatives; and antioxidants.

[0081] The term "restoration" with respect to dystrophin synthesis or production generally refers to the production of dystrophin protein, including truncated dystrophin, in a muscular dystrophy patient following treatment with an antisense oligomer or antisense oligomer conjugate described herein. In some embodiments, the treatment results in an increase of 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% (including all integers therebetween) of new dystrophin production in the patient. In some embodiments, the treatment increases the number of dystrophin-positive fibers in the subject to at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% to 100% of normal. In other embodiments, the treatment increases the number of dystrophin-positive fibers in the subject to about 20% to about 60% or about 30% to about 50% of normal. The percentage of dystrophin-positive fibers in a patient after treatment can be determined by muscle biopsy using known techniques. For example, a muscle biopsy can be taken from a suitable muscle, such as the patient's biceps.

[0082] Analysis of the percentage of positive dystrophin fibers can be performed before and / or after treatment, or at time points throughout the treatment process. In some embodiments, post-treatment biopsy is taken from the muscle contralateral to the pre-treatment biopsy. Pre-treatment and post-treatment dystrophin expression analysis can be performed using a suitable dystrophin assay. In some embodiments, immunohistochemical detection is performed on tissue sections from muscle biopsy using an antibody that is a marker for dystrophin, such as a monoclonal or polyclonal antibody. For example, MANDYS106 antibody, which is a sensitive marker for dystrophin, can be used. Any suitable secondary antibody can be used.

[0083] In some embodiments, the percentage of dystrophin-positive fibers is calculated by dividing the number of positive fibers by the total number of fibers counted. A normal muscle sample has 100% dystrophin-positive fibers. Thus, the percentage of dystrophin-positive fibers can be expressed as a percentage of normal. To control for the presence of trace levels of dystrophin in pre-treatment muscle as well as revertant fibers, a baseline can be set using pre-treatment muscle sections from the patient when counting dystrophin-positive fibers in post-treatment muscle. This can be used as a threshold for counting dystrophin-positive fibers in post-treatment muscle sections of that patient. In other embodiments, antibody-stained tissue sections can also be used for dystrophin quantification using Bioquant image analysis software (Bioquant Image Analysis Corporation, Nashville, TN). The total intensity of dystrophin fluorescent signal can be reported as a percentage of normal. Western blot analysis using monoclonal or polyclonal anti-dystrophin antibodies can also be used to determine the percentage of dystrophin-positive fibers. For example, anti-dystrophin antibody NCL-Dys1 from Leica Biosystems can be used. The percentage of dystrophin-positive fibers can also be analyzed by determining the expression of components of the sarcoglycan complex (β, γ) and / or neuronal NOS.

[0084] In some embodiments, treatment with the antisense oligomer or antisense oligomer conjugate of the present disclosure delays or reduces the progressive respiratory muscle dysfunction and / or failure in DMD patients that would be expected without treatment. In some embodiments, treatment with the antisense oligomer or antisense oligomer conjugate of the present disclosure can reduce or eliminate the need for ventilatory support that would be expected without treatment. In some embodiments, measurements of respiratory function to track disease progression and evaluate potential therapeutic interventions include maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), and forced vital capacity (FVC). MIP and MEP measure the pressure levels a person can generate during inhalation and exhalation, respectively, and are sensitive measures of respiratory muscle strength. MIP is a measure of diaphragm muscle weakness.

[0085] In some embodiments, MEP may decline before changes in other pulmonary function tests, including MIP and FVC. In certain embodiments, MEP may be an early indicator of respiratory dysfunction. In certain embodiments, FVC may be used to measure the total volume of air expelled during forced expiration after maximal inspiration. In DMD patients, FVC increases in tandem with physical growth until the early teens. However, as growth slows or becomes poorer with disease progression and muscle weakness progresses, vital capacity enters a period of decline, declining at an average rate of about 8-8.5 percent per year after age 10-12. In certain embodiments, percent predicted MIP (MIP adjusted for weight), percent predicted MEP (MEP adjusted for age), and percent predicted FVC (FVC adjusted for age and height) are supportive analyses.

[0086] As used herein, the terms "subject" and "patient" include any animal that exhibits or is at risk of exhibiting symptoms that can be treated with the antisense oligomer or antisense oligomer conjugate of the present disclosure, such as a subject (or patient) that has or is at risk of having DMD or BMD, or any of the symptoms associated with these conditions (e.g., muscle fiber loss). Suitable subjects (or patients) include laboratory animals (such as mice, rats, rabbits, or guinea pigs), livestock, and household animals or pets (such as cats or dogs). Non-human primates, and preferably human patients (or subjects) are included. Also included is a method of producing dystrophin in a subject (or patient) that has a mutation in the dystrophin gene that is suitable for exon 51 skipping.

[0087] As used herein, the phrases "systemic administration," "administered systemically," "peripheral administration," and "administered peripherally" refer to the administration of a compound, drug, or other substance directly into the central nervous system, thereby entering the patient's system and thus being subject to metabolic and other similar processes, e.g., subcutaneous administration.

[0088] The phrase "targeting sequence" refers to a sequence of nucleobases of an oligomer that is complementary to a sequence of nucleotides in a target pre-mRNA. In some embodiments of the present disclosure, the sequence of nucleotides in the target pre-mRNA is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(- 30-06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53 A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H5 3A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+2 3-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D (+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0089] In some embodiments of the present disclosure, the sequence of nucleotides in the target pre-mRNA is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+ 04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H 53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(- 10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53 A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20- 05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24). Further embodiments are described throughout this disclosure.

[0090] "Treatment" of a subject (e.g., a mammal, such as a human) or cell is any type of intervention used in an attempt to change the natural course of the subject or cell. Treatment includes, but is not limited to, administration of an oligomer or pharmaceutical composition thereof, and may be performed either prophylactically or after the onset of a pathological event or contact with a pathogen. Treatment includes any desired effect on the symptoms or pathology of a disease or condition associated with a dystrophin protein, and may include, for example, a minimal change or improvement in one or more measurable markers of the disease or condition being treated. Also included are "prophylactic" treatments, which may be aimed at slowing the rate of progression of the disease or condition being treated, delaying the onset of the disease or condition, or reducing the severity of its onset. "Treatment" or "prevention" does not necessarily indicate a complete eradication, cure, or prevention of the disease or condition or its associated symptoms.

[0091] In some embodiments, treatment with the antisense oligomer or antisense oligomer conjugate of the present disclosure increases new dystrophin production, delays disease progression, delays or reduces lameness, reduces muscle inflammation, reduces muscle damage, improves muscle function, reduces loss of lung function, and / or enhances muscle regeneration that would be expected without treatment. In some embodiments, treatment maintains, delays, or slows disease progression. In some embodiments, treatment maintains ambulation or reduces lameness. In some embodiments, treatment maintains lung function or reduces loss of lung function. In some embodiments, treatment maintains or increases the patient's stable walking distance, for example, as measured by the 6-minute walk test (6MWT). In some embodiments, treatment maintains or reduces the time to walk / run 10 meters (i.e., 10-meter walk / run test). In some embodiments, treatment maintains or reduces the time to stand up from a supine position (i.e., time to stand test). In some embodiments, treatment maintains or reduces the time to climb four standard stairs (four-stair climb test). In some embodiments, treatment maintains or reduces muscle inflammation in patients, for example, as measured by MRI (e.g., MRI of leg muscles). In some embodiments, MRI measures T2 and / or fat fraction to identify muscle degeneration. MRI can identify changes in muscle structure and composition caused by inflammation, edema, muscle damage, and fat infiltration.

[0092] In some embodiments, treatment with the antisense oligomer or antisense oligomer conjugate of the present disclosure increases new dystrophin production and delays or reduces the loss of ambulation that would be expected without treatment.For example, treatment can stabilize, maintain, improve, or increase walking ability (e.g., stabilization of ambulation) in a subject.In some embodiments, treatment maintains or increases the patient's stable walking distance, as measured by the 6-minute walk test (6MWT) described, for example, by McDonald et al. (Muscle Nerve, 2010; 42: 966-74 (hereby incorporated by reference)).The change in 6-minute walk distance (6MWD) can be expressed as absolute value, percentage change, or percent predicted change.In some embodiments, treatment maintains or improves the stable walking distance in 6MWT from a 20% deficit in the subject compared to healthy counterparts.The performance of DMD patients in 6MWT compared to the typical performance of healthy counterparts can be determined by calculating percent predicted value. For example, the % predicted 6MWD can be calculated for men using the following equation: 196.72 + (39.81 x age) - (1.36 x age) 2 ) + (132.28 × height in meters). For women, the % predicted 6MWD can be calculated using the following equation: 188.61 + (51.50 × age) - (1.86 × age 2 ) + (86.10 × height in meters) (Henricson et al. PLoS Curr., 2012, version 2, incorporated herein by reference). In some embodiments, treatment with an antisense oligomer increases stable walking distance in a patient from baseline to greater than 3, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or 50 meters (including all integers therebetween).

[0093] Loss of muscle function in DMD patients may occur against the background of normal childhood growth and development. In fact, children with DMD may show an increase in walking distance during 6MWT over the course of about one year, despite progressive muscle impairment. In some embodiments, 6MWD from DMD patients is compared to existing normative data from typically developing control subjects and age- and sex-matched subjects. In some embodiments, normal growth and development may be accounted for using an equation based on age and height fitted to normative data. Using such an equation, 6MWD may be converted to percent predicted (% predicted) values ​​in DMD patients. In certain embodiments, analysis of % predicted 6MWD data represents a way to account for normal growth and development, and may show that increases in function at a young age (e.g., 7 years or younger) represent a stabilization rather than an improvement in performance in DMD patients (Henricson et al. PLoS Curr., 2012, version 2, incorporated herein by reference).

[0094] In order to distinguish between different antisense molecules, a nomenclature system for antisense molecules has been proposed and published (see Mann et al., (2002) J Gen Med 4, 644-654). This nomenclature was particularly important when testing several slightly different antisense molecules all directed to the same target region, as shown below: H#A / D(x:y) The first letter indicates the species (e.g., H: human, M: mouse, C: dog). "#" indicates the target dystrophin exon number. "A / D" indicates the acceptor or donor splice site at the beginning and end of the exon, respectively. (xy) represents the annealing coordinates, and "-" or "+" indicates the intron or exon sequence, respectively. For example, A(-6+18) indicates the last 6 bases of the intron preceding the target exon and the first 18 bases of the target exon. The closest splice site will be the acceptor, so these coordinates are preceded by "A". The description of the annealing coordinates at the donor splice site can be D(+2-18), where the last 2 exon bases and the first 18 intron bases correspond to the annealing site of the antisense molecule. The entire exon annealing coordinate is represented by A(+65+85), ie, the site between the 65th and 85th nucleotides from the start of the exon.

[0095] II. Antisense oligomers A. Antisense oligomers and antisense oligomer conjugates designed to induce exon 53 skipping In certain embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure is complementary to the exon 53 target region of the dystrophin gene and induces the skipping of exon 53. In particular, the present disclosure relates to antisense oligomers and antisense oligomer conjugates that are complementary to the exon 53 target region of the dystrophin pre-mRNA designated as the annealing site. In some embodiments, the annealing site is as described herein.

[0096] The antisense oligomers and antisense oligomer conjugates of the present disclosure target dystrophin pre-mRNA and induce the skipping of exon 53, so that it is excluded or skipped from the mature spliced ​​mRNA transcript. By skipping exon 53, the disrupted reading frame is restored to an in-frame mutation. Although DMD consists of various genetic subtypes, the antisense oligomers and antisense oligomer conjugates of the present disclosure are specifically designed to skip exon 53 of dystrophin pre-mRNA. DMD mutations that are suitable for skipping exon 53 include a subgroup (8%) of DMD patients.

[0097] The nucleobase sequence of the antisense oligomer or antisense oligomer conjugate that induces skipping of exon 53 is designed to be complementary to a specific target sequence within exon 53 of the dystrophin pre-mRNA. In some embodiments, the antisense oligomer of the antisense oligomer or antisense oligomer conjugate is a PMO, and each morpholino ring of the PMO is linked to a nucleobase, including, for example, a nucleobase found in DNA (adenine, cytosine, guanine, and thymine).

[0098] B. Characterization of Oligomeric Chemicals The antisense oligomer and antisense oligomer conjugate of the present disclosure can use various antisense oligomer chemistries.Examples of oligomer chemistries include, but are not limited to, morpholino oligomers, phosphorothioate modified oligomers, 2'-O-methyl modified oligomers, peptide nucleic acid (PNA), locked nucleic acid (LNA), phosphorothioate oligomers, 2'-O-MOE modified oligomers, 2'-fluoro modified oligomers, 2'-O,4'C-ethylene bridged nucleic acid (ENA), tricyclo-DNA, tricyclo-DNA phosphorothioate subunits, 2'-O-[2-(N-methylcarbamoyl)ethyl] modified oligomers (including any combination of the above).Phosphorothioate and 2'-O-Me modified chemistries can be combined to produce 2'-O-Me-phosphorothioate backbone. See, e.g., PCT Publication Nos. WO / 2013 / 112053 and WO / 2009 / 008725, which are incorporated by reference in their entireties. Exemplary embodiments of the oligomeric chemicals of the present disclosure are further described below.

[0099] 1. Peptide Nucleic Acid (PNA) Peptide nucleic acids (PNAs) are analogs of DNA whose backbone is structurally homomorphic with a deoxyribose backbone and consists of N-(2-aminoethyl)glycine units to which pyrimidine or purine bases are attached. PNAs containing natural pyrimidine and purine bases hybridize to complementary oligomers according to Watson-Crick base pairing rules, mimicking DNA in terms of base pair recognition (Egholm, Buchardt et al. 1993). The backbone of PNAs is formed by peptide bonds rather than phosphodiester bonds, making them well suited for antisense applications (see structure below). The backbone is uncharged, resulting in PNA / DNA or PNA / RNA duplexes that exhibit greater than normal thermal stability. PNAs are not recognized by nucleases or proteases. Non-limiting examples of PNAs are shown below. [ka]

[0100] Despite the radical structural change relative to the natural structure, PNAs are capable of sequence-specific binding capability in a helical form to DNA or RNA. PNA features include high binding affinity to complementary DNA or RNA, destabilizing effect caused by single base mismatch, resistance to nucleases and proteases, salt-independent hybridization to DNA or RNA, and triplex formation with homopurine DNA. PANAGENE™ has developed its proprietary Bts PNA monomer (Bts; benzothiazole-2-sulfonyl group) and proprietary oligomerization process. PNA oligomerization using Bts PNA monomer consists of repeated cycles of deprotection, coupling, and capping. PNAs can be produced synthetically using any technique known in the art. For example, see U.S. Patent Nos. 6,969,766, 7,211,668, 7,022,851, 7,125,994, 7,145,006, and 7,179,896. For the preparation of PNA, see also U.S. Patent Nos. 5,539,082, 5,714,331, and 5,719,262. Further teachings of PNA compounds can be found in Nielsen et al., Science, 254:1497-1500, 1991. Each of the above is incorporated by reference in its entirety.

[0101] 2. Locked Nucleic Acid (LNA) Antisense oligomers and antisense oligomer conjugates may also contain "locked nucleic acid" subunits (LNAs). "LNAs" are members of a class of modifications called bridged nucleic acids (BNAs). BNAs are characterized by a covalent bond that locks the conformation of the ribose ring to the C30-endo (northern) sugar pucker. In the case of LNAs, the bridge is composed of a methylene between the 2'-O and 4'-C positions. LNAs enhance backbone preorganization and base stacking to enhance hybridization and thermal stability.

[0102] The structure of LNA can be found, for example, in Wengel, et al., Chemical Communications (1998) 455; Koshkin et al., Tetrahedron (1998) 54: 3607; Jesper Wengel, Accounts of Chem. Research (1999) 32: 301; Obika, et al., Tetrahedron Letters (1997) 38: 8735; Obika, et al., Tetrahedron Letters (1998) 39: 5401; and Obika, et al., Bioorganic Medicinal Chemistry (2008) 16: 9230, which are incorporated herein by reference in their entirety. Non-limiting examples of LNA are shown below. [ka]

[0103] The antisense oligomer and antisense oligomer conjugate of the present disclosure may incorporate one or more LNA.In some cases, the antisense oligomer and antisense oligomer conjugate may be completely composed of LNA.Methods for the synthesis of individual LNA nucleoside subunits and their incorporation into oligomers are described, for example, in U.S. Patent Nos. 7,572,582, 7,569,575, 7,084,125, 7,060,809, 7,053,207, 7,034,133, 6,794,499, and 6,670,461, each of which is incorporated by reference in its entirety.Exemplary intersubunit linkers include phosphodiester and phosphorothioate moieties.Alternatively, non-phosphorus-containing linkers may be used. Further embodiments include LNA-containing antisense oligomers or antisense oligomer conjugates, where each LNA subunit is separated by a DNA subunit. Certain antisense oligomers or antisense oligomer conjugates are composed of alternating LNA and DNA subunits, where the intersubunit linker is phosphorothioate.

[0104] 2'O,4'C-Ethylene-bridged Nucleic Acids (ENAs) are another member of the BNA class. Non-limiting examples are provided below. [ka]

[0105] ENA oligomers and their preparation are described in Obika et al., Tetrahedron Lett (1997) 38(50):8735, which is incorporated herein by reference in its entirety. The antisense oligomers and antisense oligomer conjugates of the present disclosure may incorporate one or more ENA subunits.

[0106] 3. Unlocked Nucleic Acid (UNA) Antisense oligomers and antisense oligomer conjugates may also contain "unlocked nucleic acid" (UNA) subunits. UNA and UNA oligomers are analogs of RNA with the C2'-C3' bond of the subunits cleaved. LNAs are conformationally restricted (relative to DNA and RNA), whereas UNAs are highly flexible. UNAs are disclosed, for example, in WO2016 / 070166. Non-limiting examples of UNAs are shown below. [ka]

[0107] Exemplary intersubunit linkers include phosphodiester and phosphorothioate moieties. Alternatively, non-phosphorus-containing linkers may be used.

[0108] 4. Phosphorothioates "Phosphorothioates" (or S-oligos) are variants of normal DNA in which one of the non-bridging oxygens is replaced by a sulfur. Non-limiting examples of phosphorothioates are shown below. [ka]

[0109] Sulfurization of internucleotide bonds reduces the action of endo- and exonucleases, including 5' to 3' and 3' to 5' DNA POL1 exonuclease, nucleases S1 and P1, RNases, serum nucleases, and snake venom phosphodiesterases. Phosphorothioates are made by two major routes: the action of a solution of elemental sulfur in carbon disulfide on hydrogen phosphonates, or sulfurization of phosphite triesters with either tetraethylthiuram disulfide (TETD) or 3H-1,2-benzodithiol-3-one 1,1-dioxide (BDTD) (see, e.g., J. Org. Chem. 55, 4693-4699, 1990, incorporated herein by reference in its entirety). The latter method avoids the problems of the insolubility of elemental sulfur in most organic solvents and the toxicity of carbon disulfide. The TETD and BDTD methods also result in phosphorothioates of higher purity.

[0110] 5. Tricyclo-DNA and Tricyclo-phosphorothioate Subunits Tricyclo-DNA (tc-DNA) is a class of constrained DNA analogues in which each nucleotide is modified by the introduction of a cyclopropane ring to restrict the conformational flexibility of the backbone and optimize the backbone geometry of the torsion angle γ. Homobasic adenine and thymine-containing tc-DNA forms highly stable AT base pairs with complementary RNA. Tricyclo-DNA and its synthesis are described in International Patent Application Publication No. WO2010 / 115993, which is incorporated herein by reference in its entirety. The antisense oligomers and antisense oligomer conjugates of the present disclosure may incorporate one or more tricyclo-DNA subunits. In some cases, the antisense oligomer or antisense oligomer conjugate may be entirely composed of tricyclo-DNA subunits.

[0111] Tricyclo-phosphorothioate subunits are tricyclo-DNA subunits with phosphorothioate intersubunit linkages.Tricyclo-phosphorothioate subunits and their synthesis are described in International Patent Application Publication No. WO2013 / 053928, which is incorporated herein by reference in its entirety.The antisense oligomers and antisense oligomer conjugates of the present disclosure can incorporate one or more tricyclo-DNA subunits.In some cases, the antisense oligomers and antisense oligomer conjugates can be completely composed of tricyclo-DNA subunits.Non-limiting examples of tricyclo-DNA / tricyclo-phosphothioate are shown below. [ka]

[0112] 6. 2'-O-Methyl, 2'-O-MOE, and 2'-F Oligomers "2'-O-Me oligomer" molecules have a methyl group at the 2'-OH residue of the ribose molecule. 2'-O-Me-RNA behaves the same (or similar) as DNA, but is protected from nuclease degradation. 2'-O-Me-RNA can also be combined with phosphorothioate oligomers (PTO) for further stabilization. 2'O-Me oligomers (phosphodiester or phosphothioate) can be synthesized according to conventional techniques in the art (see, for example, Yoo et al., Nucleic Acids Res. 32:2008-16, 2004, which is incorporated herein by reference in its entirety). Non-limiting examples of 2'O-Me oligomers are shown below. [ka]

[0113] 2'-O-Methoxyethyl oligomers (2'-O MOE) have a methoxyethyl group at the 2'-OH residue of the ribose molecule and are discussed in Martin et al., Helv. Chim. Acta, 78, 486-504, 1995, which is incorporated herein by reference in its entirety. Non-limiting examples of 2'O MOE subunits are shown below. [ka]

[0114] 2'-Fluoro (2'-F) oligomers have a fluorescent radical at the 2' position instead of the 2'OH. Non-limiting examples of 2'-F oligomers are shown below. [ka] 2'-Fluoro oligomers are further described in WO2004 / 043977, which is incorporated herein by reference in its entirety.

[0115] The 2'-O-Methyl, 2'-O-MOE, and 2'-F oligomers may also contain one or more phosphorothioate (PS) linkages, as illustrated below. [ka]

[0116] Additionally, 2'-O-methyl, 2'-O-MOE, and 2'-F oligomers may contain PS intersubunit linkages throughout the oligomer, such as, for example, the 2'-O-methyl PS oligomer drisapersen shown below. [ka]

[0117] Alternatively, the 2'-O-methyl, 2'-O-MOE, and / or 2'-F oligomers may contain a PS linkage at the terminus of the oligomer, as illustrated below. [ka] During the ceremony, R is CH 2 CH 2 OCH 3 (methoxyethyl or MOE), x, y, and z represent the number of nucleotides contained within the designated 5'-wing, central gap, and 3'-wing regions, respectively.

[0118] The antisense oligomer and antisense oligomer conjugate of the present disclosure may incorporate one or more 2'O-methyl, 2'O-MOE, and 2'-F subunits and may utilize any of the intersubunit linkages described herein.In some cases, the antisense oligomer or antisense oligomer conjugate of the present disclosure may be completely composed of 2'-O-methyl, 2'-O-MOE, or 2'-F subunits.One embodiment of the antisense oligomer or antisense oligomer conjugate of the present disclosure is completely composed of 2'-O-methyl subunits.

[0119] 7. 2'-O-[2-(N-methylcarbamoyl)ethyl] oligomer (MCE) MCE is another example of a 2'O modified ribonucleoside useful in the antisense oligomers and antisense oligomer conjugates of the present disclosure, where the 2'OH is derivatized to a 2-(N-methylcarbamoyl)ethyl moiety to enhance nuclease resistance. A non-limiting example of an MCE oligomer is shown below. [ka] MCE and its synthesis are discussed in Yamada et al., J. Org. Chem. (2011) 76(9):3042-53, which is incorporated herein by reference in its entirety. Antisense oligomers and antisense oligomer conjugates of the present disclosure may incorporate one or more MCE subunits.

[0120] 8. Stereospecific Oligomers Stereospecific oligomers are those in which the stereochemistry of each phosphorus-containing linkage is fixed by synthetic methods such that substantially stereopure oligomers are produced. Non-limiting examples of stereospecific oligomers are shown below. [ka]

[0121] In the above example, each phosphorus of oligomer has the same stereochemistry.Further examples include the above oligomer.For example, LNA, ENA, tricyclo-DNA, MCE, 2'-O-methyl, 2'-O-MOE, 2'-F and morpholino-based oligomers can be prepared with stereospecific phosphorus-containing internucleoside linkage, for example phosphorothioate, phosphodiester, phosphoramidate, phosphorodiamidate or other phosphorus-containing internucleoside linkage. Stereospecific oligomers, methods of preparation, chiral controlled synthesis, chiral designs, and chiral auxiliaries for use in the preparation of such oligomers are described, for example, in WO2017192664, WO2017192679, WO2017062862, WO2017015575, WO2017015555, WO2015107425, WO2015108048, This is described in detail in WO2015108046, WO2015108047, WO2012039448, WO2010064146, WO2011034072, WO2014010250, WO2014012081, WO20130127858, and WO2011005761, each of which is incorporated by reference in its entirety.

[0122] The stereospecific oligomer is R P or S PThe oligomer may have a phosphorus-containing internucleoside linkage in any configuration. A chiral phosphorus-containing linkage in which the configuration of the linkage is controlled is referred to as "stereo-pure" and a chiral phosphorus-containing linkage in which the configuration of the linkage is not controlled is referred to as "stereoirregular". In certain embodiments, the oligomer of the present disclosure includes a plurality of stereo-pure and stereoirregular linkages, whereby the resulting oligomer has a stereo-pure subunit at a pre-specified position of the oligomer. Examples of the positions of stereo-pure subunits are provided in International Patent Application Publication No. WO2017 / 062862A2 in Figures 7A and 7B. In one embodiment, all chiral phosphorus-containing linkages in the oligomer are stereoirregular. In one embodiment, all chiral phosphorus-containing linkages in the oligomer are stereo-pure.

[0123] In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), all n of the chiral phosphorus-containing linkages in the oligomer are stereoirregular. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), all n of the chiral phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 10% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 20% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 30% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 40% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 50% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 60% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages (n is an integer equal to or greater than 1), at least 70% (rounded to the nearest whole number) of the n phosphorus-containing linkages in the oligomer are stereopure. In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, at least 80% (rounded to the nearest integer) of the n phosphorus-containing linkages in the oligomer are stereopure.In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, at least 90% (rounded to the nearest integer) of the n phosphorus-containing linkages in the oligomer are stereopure.

[0124] In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least two consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least three consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least four consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least five consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least six consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R PIn one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least seven consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least eight consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least nine consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 10 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 11 contiguous stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 12 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 13 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R PIn one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 14 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 15 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 16 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 17 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer has at least 18 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P In one embodiment of an oligomer having n chiral phosphorus-containing linkages, where n is an integer equal to or greater than 1, the oligomer contains at least 19 consecutive stereopure phosphorus-containing linkages of the same configuration (i.e., S P or R P The compound contains at least 20 consecutive stereopure phosphorus-containing linkages of the formula (I) or (II).

[0125] 9. Morpholino Oligomers Exemplary embodiments of the present disclosure include compounds having the following general structure: [ka] and as described in Figure 2 of Summerton, J., et al., Antisense & Nucleic Acid Drug Development, 7:187-195 (1997). The morpholino described herein is intended to include all stereoisomers and tautomers of the above general structure. The synthesis, structure and binding properties of morpholino oligomers are described in detail in U.S. Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, 5,506,337, 8,076,476 and 8,299,206, all of which are incorporated herein by reference.

[0126] In certain embodiments, the morpholinos are conjugated to a "tail" moiety at the 5' or 3' end of the oligomer to enhance its stability and / or solubility. Exemplary tails include: [ka] Includes.

[0127] In various embodiments, the antisense oligomer conjugates of the present disclosure are according to formula (I): [ka] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase that together form a targeting sequence, T, [ka] is selected from R 1 But, C 1 ~C 6 is alkyl, The targeting sequence is complementary to the exon 53 annealing site in the dystrophin pre-mRNA.

[0128] In some embodiments, the targeting sequence is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A(-25 -01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53 A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H 53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53 D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11) , H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 1-65. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 70-134.

[0129] In some embodiments, the targeting sequence is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-22+06), H53A(-22+07), H53A(-22+08), H53A(-22+09), H53A(-23+01), H53A(-23+02), H53A(-22+03), H53A(-22+04), H53A(-22+05), H53A(-22+06), H53A(-22+07), H53A(- ), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H 53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A (-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA selected from the group consisting of H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0130] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 12-14, 16-31, 33-35, 39-46, 48, 49, 52, 53, 58, and 64.

[0131] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83, 85-100, 102-104, 108-115, 117, 118, 121, 122, 127, and 133.

[0132] In some embodiments, the targeting sequence is complementary to the exon 53 annealing site in the dystrophin pre-mRNA within H53A(-23+15).

[0133] In some embodiments, the annealing site is selected from the group consisting of H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(11+14), and H53A(-10+15).

[0134] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 18-31. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 87-100.

[0135] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53A(-16+16). In some embodiments, the annealing site is selected from the group consisting of H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), and H53A(-9+16). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 49-56. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 115-125.

[0136] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA within H53A(-8+20). In some embodiments, the annealing site is selected from the group consisting of H53A(-8+17), H53A(-7+18), H53A(-6+19), and H53A(-5+20). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 33-36. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 102-105.

[0137] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53D(+23-09). In some embodiments, the annealing site is selected from the group consisting of H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18 07), H53D(+17-08), and H53D(+16-09). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-49. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-118.

[0138] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53D(+22-15). In some embodiments, the annealing site is selected from the group consisting of H53D(+22-03), H53D(+20-05), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), and H53D(+10-15). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 43, 45, and 50-55. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 112, 114, and 119-124.

[0139] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA that is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0140] In some embodiments, the targeting sequence is within intron 52 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA, which is within H53A(-100-01). In some embodiments, the annealing site is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), and H53A(-25-01). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 1-16. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 70-85.

[0141] In some embodiments, the targeting sequence is within intron 52 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA, which is within H53A(-45-01). In some embodiments, the annealing site is selected from H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 12-14 and 16. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83 and 85. In some embodiments, the annealing site is H53A(-35-11). In some embodiments, the targeting sequence is SEQ ID NO: 14. In some embodiments, the targeting sequence is SEQ ID NO: 83.

[0142] In some embodiments, the targeting sequence spans the exon 53 acceptor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53A(-24+24). In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-15+12), H53A(-15+13), H53A(-15+14), H53A(-15+15), H53A(-15+16), H53A(-15+17), H53A(-15+18), H53A(-15+19), H53A(-16+19), H53A(-16+20), H53A(-16+21), H53A(-16+22), H53A(-16+23), H53A(-16+24), H53A(-16+25), H53A(-16+26), H53A(-16+27), H53A(-16+28), H53A(-16+29), H53A(-17+30), H53A(-17+31), H53A(-17+32), H53A(-17+33), H53A(-17+34), H53A(-17+35), H53A(- In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 17-40. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 86-109. In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+ In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 17-31, 33-36, 39, and 40. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 86-100, 102-105, 108, and 109.

[0143] In some embodiments, the targeting sequence spans the exon 53 donor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53D(+24-24). In some embodiments, the annealing site is H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+15-22), H53D(+15-23), H53D(+15-24), H53D(+15-25), H53D(+15-26), H53D(+15-27), H53D(+15-28), H53D(+15-29), H53D(+16-30), H53D(+16-31), H53D(+16-32), H53D(+16-33), H53D(+16-34), H53D(+16-35), H53D(+16-36), H53D(+16-37), H53D(+16-38), H53D(+16-39), H53D(+17-40), H53D(+17-41), H53D(+17-42), H53D(+17-43), H53D(+17-44), H53D(+17-45), H53D(+17-46), H53D(+ In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-64. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-133. In some embodiments, the annealing site is selected from H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+7-18), H53D(+2-23), and H53D(+1-24). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-46, 48, 49, 51-55, 58, 63, and 64. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-115, 117, 118, 120-124, 127, 132, and 133.

[0144] In some embodiments, the targeting sequence spans the exon 53 donor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53D(+22-15). In some embodiments, the annealing site is selected from H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), and H53D(+10-15). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 43-55. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 112-124.

[0145] In some embodiments, the targeting sequence is within intron 53 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA designated as H53D(-1-25). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NO: 66. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NO: 135.

[0146] In various embodiments, T is [ka] It is.

[0147] In various embodiments, R 1 CF 3 , CCl 3 , CFCl 2 , C.F. 2 Cl, ethyl, CH 2 CF 3 , C.F. 2 CF 3, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, or 2,3-dimethylbutyl.

[0148] In some embodiments, the antisense oligomer conjugate of formula (I) is its HCl (hydrochloric acid) salt. In certain embodiments, the HCl salt is a .6HCl salt.

[0149] In some embodiments, each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0150] In various embodiments, T is [ka] and the targeting sequence is selected from: [Table 1-1] [Table 1-2] Each X is independently thymine (T) or uracil (U). In some embodiments, each X is independently T.

[0151] In various embodiments, T is [ka] and the targeting sequence is selected from: [Table 2-1] [Table 2-2]

[0152] In some embodiments, including for example some embodiments of formula (I), the antisense oligomer conjugates of the present disclosure are according to formula (II): [ka] or a pharma- ceutically acceptable salt thereof, Each Nu is a nucleobase that together form a targeting sequence that is complementary to an exon 53 annealing site in the dystrophin pre-mRNA.

[0153] In some embodiments, the annealing site is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30- 06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A( -9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D( +24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-0) 9), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0154] In some embodiments, the annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), ), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H 53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H5 H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0155] In some embodiments, the annealing site is within H53A(-23+15). In some embodiments, the annealing site is selected from the group consisting of H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(11+14), and H53A(-10+15).

[0156] In some embodiments, the annealing site is within H53A(-16+16). In some embodiments, the annealing site is selected from the group consisting of H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), and H53A(-9+16).

[0157] In some embodiments, the annealing site is within H53A(-8+20). In some embodiments, the annealing site is selected from the group consisting of H53A(-8+17), H53A(-7+18), H53A(-6+19), and H53A(-5+20).

[0158] In some embodiments, the annealing site is within H53D(+23-09). In some embodiments, the annealing site is selected from the group consisting of H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18 07), H53D(+17-08), and H53D(+16-09).

[0159] In some embodiments, the annealing site is within H53D(+22-15). In some embodiments, the annealing site is selected from the group consisting of H53D(+22-03), H53D(+20-05), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0160] In some embodiments, the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0161] In some embodiments, the annealing site is within intron 52, within H53A(-100-01). In some embodiments, the annealing site is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), and H53A(-25-01).

[0162] In some embodiments, the annealing site is within intron 52 and is within H53A(-45-01). In some embodiments, the annealing site is selected from H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01). In some embodiments, the annealing site is H53A(-35-11).

[0163] In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+24). In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-15+12), H53A(-15+13), H53A(-15+14), H53A(-15+15), H53A(-15+16), H53A(-15+17), H53A(-15+18), H53A(-15+19), H53A(-16+19), H53A(-16+20), H53A(-16+21), H53A(-16+22), H53A(-16+23), H53A(-16+24), H53A(-16+25), H53A(-16+26), H53A(-16+27), H53A(-16+28), H53A(-16+29), H53A(-17+30), H53A(-17+31), H53A(-17+32), H53A(-17+33), H53A(-17+34), H53A(-17+35), H53A(-17+36), H H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), and H53A(-1+24). In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+ 10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), and H53A(-1+24).

[0164] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+24-24). In some embodiments, the annealing site is within H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+15-22), H53D(+15-23), H53D(+15-24), H53D(+15-25), H53D(+15-26), H53D(+15-27), H53D(+15-28), H53D(+15-29), H53D(+16-30), H53D(+16-31), H53D(+16-32), H53D(+16-33), H53D(+16-34), H53D(+16-35), H53D(+16-36), H53D(+16-37), H53D(+16-38), H53D(+16-39), H53D(+17-40), H53D(+17-41), H53D(+17-42), H53D(+17-43), H53D(+17-44), H53D(+17-45), H53D(+17-46), H53D(+17-47), H53D(+17-48), H53D H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), and H53D(+1-24). In some embodiments, the annealing site is selected from H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17 08), H53D(+16-09), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), H53D(+10-15), H53D(+7-18), H53D(+2-23), and H53D(+1-24).

[0165] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+22-15). In some embodiments, the annealing site is selected from H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17 08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13 12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0166] In some embodiments, the annealing site is within intron 53 and is designated H53D(-1-25).

[0167] In some embodiments, each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0168] In various embodiments, the targeting sequence is selected from the following: [Table 3-1] [Table 3-2] Here, A is [ka] and C is [ka] and G is [ka] and X is [ka] In certain embodiments, each X is independently [ka] It is.

[0169] In various embodiments, the targeting sequence is selected from the following: [Table 4-1] [Table 4-2] Here, A is [ka] and C is [ka] and G is [ka] and T is [ka] It is.

[0170] In some embodiments, the antisense oligomer conjugate of formula (II) is its HCl (hydrochloric acid) salt. In certain embodiments, the HCl salt is a .6HCl salt.

[0171] In some embodiments, including, for example, some embodiments of formula (II), the antisense oligomer conjugates of the present disclosure are according to formula (III): [ka] or a pharma- ceutically acceptable salt thereof, Z is an integer from 16 to 23; Each Nu is a nucleobase that together form a targeting sequence that is complementary to an exon 53 annealing site in the dystrophin pre-mRNA.

[0172] In some embodiments, the annealing site is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30- 06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A( -9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D( +24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-0) 9), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0173] In some embodiments, the annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), ), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H 53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H5 H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0174] In some embodiments, the annealing site is within H53A(-23+15). In some embodiments, the annealing site is selected from the group consisting of H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(11+14), and H53A(-10+15).

[0175] In some embodiments, the annealing site is within H53A(-16+16). In some embodiments, the annealing site is selected from the group consisting of H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), and H53A(-9+16).

[0176] In some embodiments, the annealing site is within H53A(-8+20). In some embodiments, the annealing site is selected from the group consisting of H53A(-8+17), H53A(-7+18), H53A(-6+19), and H53A(-5+20).

[0177] In some embodiments, the annealing site is within H53D(+23-09). In some embodiments, the annealing site is selected from the group consisting of H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18 07), H53D(+17-08), and H53D(+16-09).

[0178] In some embodiments, the annealing site is within H53D(+22-15). In some embodiments, the annealing site is selected from the group consisting of H53D(+22-03), H53D(+20-05), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0179] In some embodiments, the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0180] In some embodiments, the annealing site is within intron 52, within H53A(-100-01). In some embodiments, the annealing site is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), and H53A(-25-01).

[0181] In some embodiments, the annealing site is within intron 52 and is within H53A(-45-01). In some embodiments, the annealing site is selected from H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01). In some embodiments, the annealing site is H53A(-35-11).

[0182] In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+24). In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-15+12), H53A(-15+13), H53A(-15+14), H53A(-15+15), H53A(-15+16), H53A(-15+17), H53A(-15+18), H53A(-15+19), H53A(-16+19), H53A(-16+20), H53A(-16+21), H53A(-16+22), H53A(-16+23), H53A(-16+24), H53A(-16+25), H53A(-16+26), H53A(-16+27), H53A(-16+28), H53A(-16+29), H53A(-17+30), H53A(-17+31), H53A(-17+32), H53A(-17+33), H53A(-17+34), H53A(-17+35), H53A(-17+36), H H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), and H53A(-1+24). In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+ 10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), and H53A(-1+24).

[0183] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+24-24). In some embodiments, the annealing site is within H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+15-22), H53D(+15-23), H53D(+15-24), H53D(+15-25), H53D(+15-26), H53D(+15-27), H53D(+15-28), H53D(+15-29), H53D(+16-30), H53D(+16-31), H53D(+16-32), H53D(+16-33), H53D(+16-34), H53D(+16-35), H53D(+16-36), H53D(+16-37), H53D(+16-38), H53D(+16-39), H53D(+17-40), H53D(+17-41), H53D(+17-42), H53D(+17-43), H53D(+17-44), H53D(+17-45), H53D(+17-46), H53D(+17-47), H53D(+17-48), H53D H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), and H53D(+1-24). In some embodiments, the annealing site is selected from H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17 08), H53D(+16-09), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), H53D(+10-15), H53D(+7-18), H53D(+2-23), and H53D(+1-24).

[0184] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+22-15). In some embodiments, the annealing site is selected from H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17 08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13 12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0185] In some embodiments, the annealing site is within intron 53 and is designated H53D(-1-25).

[0186] In some embodiments, each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0187] In various embodiments, the targeting sequence is selected from the following: [Table 5-1] [Table 5-2] Here, A is [ka] and C is [ka] and G is [ka] and X is [ka] In certain embodiments, each X is independently [ka] It is.

[0188] In various embodiments, the targeting sequence is selected from the following: [Table 6-1] [Table 6-2] Here, A is [ka] and C is [ka] and G is [ka] and T is [ka] It is.

[0189] In various embodiments, the antisense oligomer of the disclosure is according to formula (IV): [ka] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase that together form a targeting sequence, T, [ka] is a moiety selected from R 1 But, C 1 ~C 6 is alkyl, R 2 is selected from H or acetyl; The targeting sequence is complementary to the exon 53 annealing site in the dystrophin pre-mRNA.

[0190] In some embodiments, the targeting sequence is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), H53A(-25 -01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53 A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H 53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53 D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11) , H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 1-65. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 70-134.

[0191] In some embodiments, the targeting sequence is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-22+06), H53A(-22+07), H53A(-22+08), H53A(-22+09), H53A(-23+01), H53A(-23+02), H53A(-22+03), H53A(-22+04), H53A(-22+05), H53A(-22+06), H53A(-22+07), H53A(- ), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H 53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A (-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA selected from the group consisting of H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0192] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 12-14, 16-31, 33-35, 39-46, 48, 49, 52, 53, 58, and 64.

[0193] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83, 85-100, 102-104, 108-115, 117, 118, 121, 122, 127, and 133.

[0194] In some embodiments, the targeting sequence is complementary to the exon 53 annealing site in the dystrophin pre-mRNA within H53A(-23+15).

[0195] In some embodiments, the annealing site is selected from the group consisting of H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(11+14), and H53A(-10+15).

[0196] In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 18-31. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 87-100.

[0197] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53A(-16+16). In some embodiments, the annealing site is selected from the group consisting of H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), and H53A(-9+16). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 49-56. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 115-125.

[0198] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA within H53A(-8+20). In some embodiments, the annealing site is selected from the group consisting of H53A(-8+17), H53A(-7+18), H53A(-6+19), and H53A(-5+20). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 33-36. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 102-105.

[0199] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53D(+23-09). In some embodiments, the annealing site is selected from the group consisting of H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18 07), H53D(+17-08), and H53D(+16-09). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-49. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-118.

[0200] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in the dystrophin pre-mRNA in H53D(+22-15). In some embodiments, the annealing site is selected from the group consisting of H53D(+22-03), H53D(+20-05), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), and H53D(+10-15). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 43, 45, and 50-55. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 112, 114, and 119-124.

[0201] In some embodiments, the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA that is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0202] In some embodiments, the targeting sequence is within intron 52 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA, which is within H53A(-100-01). In some embodiments, the annealing site is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), and H53A(-25-01). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 1-16. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 70-85.

[0203] In some embodiments, the targeting sequence is within intron 52 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA, which is within H53A(-45-01). In some embodiments, the annealing site is selected from H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 12-14 and 16. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 81-83 and 85. In some embodiments, the annealing site is H53A(-35-11). In some embodiments, the targeting sequence is SEQ ID NO: 14. In some embodiments, the targeting sequence is SEQ ID NO: 83.

[0204] In some embodiments, the targeting sequence spans the exon 53 acceptor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53A(-24+24). In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-15+12), H53A(-15+13), H53A(-15+14), H53A(-15+15), H53A(-15+16), H53A(-15+17), H53A(-15+18), H53A(-15+19), H53A(-16+19), H53A(-16+20), H53A(-16+21), H53A(-16+22), H53A(-16+23), H53A(-16+24), H53A(-16+25), H53A(-16+26), H53A(-16+27), H53A(-16+28), H53A(-16+29), H53A(-17+30), H53A(-17+31), H53A(-17+32), H53A(-17+33), H53A(-17+34), H53A(-17+35), H53A(- In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 17-40. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 86-109. In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+ In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 17-31, 33-36, 39, and 40. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 86-100, 102-105, 108, and 109.

[0205] In some embodiments, the targeting sequence spans the exon 53 donor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53D(+24-24). In some embodiments, the annealing site is H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+15-22), H53D(+15-23), H53D(+15-24), H53D(+15-25), H53D(+15-26), H53D(+15-27), H53D(+15-28), H53D(+15-29), H53D(+16-30), H53D(+16-31), H53D(+16-32), H53D(+16-33), H53D(+16-34), H53D(+16-35), H53D(+16-36), H53D(+16-37), H53D(+16-38), H53D(+16-39), H53D(+17-40), H53D(+17-41), H53D(+17-42), H53D(+17-43), H53D(+17-44), H53D(+17-45), H53D(+17-46), H53D(+ In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-64. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-133. In some embodiments, the annealing site is selected from H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+7-18), H53D(+2-23), and H53D(+1-24). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 41-46, 48, 49, 51-55, 58, 63, and 64. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 110-115, 117, 118, 120-124, 127, 132, and 133.

[0206] In some embodiments, the targeting sequence spans the exon 53 donor splice site and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA located within H53D(+22-15). In some embodiments, the annealing site is selected from H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), and H53D(+10-15). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 43-55. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NOs: 112-124.

[0207] In some embodiments, the targeting sequence is within intron 53 and is complementary to an exon 53 annealing site in the dystrophin pre-mRNA designated as H53D(-1-25). In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NO: 66. In some embodiments, the targeting sequence is selected from the group consisting of SEQ ID NO: 135.

[0208] In various embodiments, T is [ka] It is.

[0209] In various embodiments, R 1 CF 3 , CCl 3 , CFCl 2 , C.F. 2 Cl, ethyl, CH 2 CF 3 , C.F. 2 CF 3, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, or 2,3-dimethylbutyl.

[0210] In some embodiments, each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0211] In various embodiments, T is [ka] and the targeting sequence is selected from: [Table 7-1] [Table 7-2] Each X is independently thymine (T) or uracil (U). In some embodiments, each X is independently T.

[0212] In various embodiments, T is [ka] and the targeting sequence is selected from: [Table 8-1] [Table 8-2]

[0213] In some embodiments, including, for example, some embodiments of formula (IV), the antisense oligomer of the disclosure is according to formula (V): [ka] or a pharma- ceutically acceptable salt thereof, R is selected from H or acetyl; Each Nu is a nucleobase that together form a targeting sequence that is complementary to an exon 53 annealing site in the dystrophin pre-mRNA.

[0214] In some embodiments, the annealing site is H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30- 06), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A( -9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), H53A(-1+24), H53D( +24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-0) 9), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), H53D(+1-24), and H53D(-01-25).

[0215] In some embodiments, the annealing site is H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01), H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), ), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H 53A(-2+23), H53A(-1+24), H53D(+24-01), H53D(+23-02), H53D(+22-03), H5 H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17-08), H53D(+16-09), H53D(+13-12), H53D(+12-13), H53D(+7-18), and H53D(+1-24).

[0216] In some embodiments, the annealing site is within H53A(-23+15). In some embodiments, the annealing site is selected from the group consisting of H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(11+14), and H53A(-10+15).

[0217] In some embodiments, the annealing site is within H53A(-16+16). In some embodiments, the annealing site is selected from the group consisting of H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), and H53A(-9+16).

[0218] In some embodiments, the annealing site is within H53A(-8+20). In some embodiments, the annealing site is selected from the group consisting of H53A(-8+17), H53A(-7+18), H53A(-6+19), and H53A(-5+20).

[0219] In some embodiments, the annealing site is within H53D(+23-09). In some embodiments, the annealing site is selected from the group consisting of H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18 07), H53D(+17-08), and H53D(+16-09).

[0220] In some embodiments, the annealing site is within H53D(+22-15). In some embodiments, the annealing site is selected from the group consisting of H53D(+22-03), H53D(+20-05), H53D(+15-10), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0221] In some embodiments, the annealing site is within intron 52, spans the exon 53 acceptor splice site, spans the exon 53 donor splice site, or is within intron 53.

[0222] In some embodiments, the annealing site is within intron 52, within H53A(-100-01). In some embodiments, the annealing site is selected from the group consisting of H53A(-100-76), H53A(-95-71), H53A(-90-66), H53A(-85-61), H53A(-80-56), H53A(-75-51), H53A(-70-46), H53A(-65-41), H53A(-60-36), H53A(-55-31), H53A(-50-26), H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-30-06), and H53A(-25-01).

[0223] In some embodiments, the annealing site is within intron 52 and is within H53A(-45-01). In some embodiments, the annealing site is selected from H53A(-45-21), H53A(-40-16), H53A(-35-11), H53A(-25-01). In some embodiments, the annealing site is H53A(-35-11).

[0224] In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+24). In some embodiments, the annealing site spans the exon 53 acceptor splice site and is within H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+10), H53A(-14+11), H53A(-15+12), H53A(-15+13), H53A(-15+14), H53A(-15+15), H53A(-15+16), H53A(-15+17), H53A(-15+18), H53A(-15+19), H53A(-16+19), H53A(-16+20), H53A(-16+21), H53A(-16+22), H53A(-16+23), H53A(-16+24), H53A(-16+25), H53A(-16+26), H53A(-16+27), H53A(-16+28), H53A(-16+29), H53A(-17+30), H53A(-17+31), H53A(-17+32), H53A(-17+33), H53A(-17+34), H53A(-17+35), H53A(-17+36), H H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-9+16), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-4+21), H53A(-3+22), H53A(-2+23), and H53A(-1+24). In some embodiments, the annealing site is H53A(-24+01), H53A(-23+02), H53A(-22+03), H53A(-21+04), H53A(-20+05), H53A(-19+06), H53A(-18+07), H53A(-17+08), H53A(-16+09), H53A(-15+ 10), H53A(-14+11), H53A(-13+12), H53A(-12+13), H53A(-11+14), H53A(-10+15), H53A(-8+17), H53A(-7+18), H53A(-6+19), H53A(-5+20), H53A(-2+23), and H53A(-1+24).

[0225] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+24-24). In some embodiments, the annealing site is within H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17-08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+15-22), H53D(+15-23), H53D(+15-24), H53D(+15-25), H53D(+15-26), H53D(+15-27), H53D(+15-28), H53D(+15-29), H53D(+16-30), H53D(+16-31), H53D(+16-32), H53D(+16-33), H53D(+16-34), H53D(+16-35), H53D(+16-36), H53D(+16-37), H53D(+16-38), H53D(+16-39), H53D(+17-40), H53D(+17-41), H53D(+17-42), H53D(+17-43), H53D(+17-44), H53D(+17-45), H53D(+17-46), H53D(+17-47), H53D(+17-48), H53D H53D(+13-12), H53D(+12-13), H53D(+11-14), H53D(+10-15), H53D(+9-16), H53D(+8-17), H53D(+7-18), H53D(+6-19), H53D(+5-20), H53D(+4-21), H53D(+3-22), H53D(+2-23), and H53D(+1-24). In some embodiments, the annealing site is selected from H53D(+24-01), H53D(+23-02), H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+17 08), H53D(+16-09), H53D(+14-11), H53D(+13-12), H53D(+12-13), H53D(+11 14), H53D(+10-15), H53D(+7-18), H53D(+2-23), and H53D(+1-24).

[0226] In some embodiments, the annealing site spans the exon 53 donor splice site and is within H53D(+22-15). In some embodiments, the annealing site is selected from H53D(+22-03), H53D(+21-04), H53D(+20-05), H53D(+19-06), H53D(+18-07), H53D(+17 08), H53D(+16-09), H53D(+15-10), H53D(+14-11), H53D(+13 12), H53D(+12-13), H53D(+11 14), and H53D(+10-15).

[0227] In some embodiments, the annealing site is within intron 53 and is designated H53D(-1-25).

[0228] In some embodiments, each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0229] In various embodiments, the targeting sequence is selected from the following: [Table 9-1] [Table 9-2] Here, A is [ka] and C is [ka] and G is [ka] and X is [ka] In certain embodiments, each X is independently [ka] It is.

[0230] In various embodiments, the targeting sequence is selected from the following: [Table 10-1] [Table 10-2] Here, A is [ka] and C is [ka] and G is [ka] and T is [ka] It is.

[0231] 10. Nucleobase Modifications and Substitutions In certain embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure is composed of RNA nucleobases and DNA nucleobases (often simply referred to as "bases" in the art). RNA bases are commonly known as adenine (A), uracil (U), cytosine (C), and guanine (G). DNA bases are commonly known as adenine (A), thymine (T), cytosine (C), and guanine (G). In various embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure is composed of cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

[0232] In certain embodiments, one or more RNA or DNA bases in an oligomer may be modified or replaced with a base other than an RNA or DNA base. Oligomers containing modified or replaced bases include oligomers in which one or more of the purine or pyrimidine bases most commonly found in nucleic acids are replaced with a less common or unnatural base.

[0233] Purine bases contain a pyrimidine ring fused to an imidazole ring, as described by the general formula below: [ka] Adenine and guanine are the two most commonly found purine nucleobases in nucleic acids. Other naturally occurring purines include N 6 -Methyladenine, N 2 Examples of methylguanine include, but are not limited to, -methylguanine, hypoxanthine, and 7-methylguanine.

[0234] The pyrimidine base contains a six-membered pyrimidine ring, as described by the general formula: [ka] Cytosine, uracil and thymine are the most commonly found pyrimidine bases in nucleic acid.Other naturally occurring pyrimidines include, but are not limited to, 5-methylcytosine, 5-hydroxymethylcytosine, pseudouracil and 4-thiouracil.In one embodiment, the oligomer described herein contains thymine base instead of uracil.

[0235] Other suitable bases include 2,6-diaminopurine, orotic acid, agmatidine, lysidine, 2-thiopyrimidines (e.g., 2-thiouracil, 2-thiothymine), G-clamps and derivatives thereof, 5-substituted pyrimidines (e.g., 5-halouracil, 5-propynyluracil, 5-propynylcytosine, 5-aminomethyluracil, 5-hydroxymethyluracil, 5-aminomethylcytosine, 5-hydroxymethylcytosine, Super T), 7-deazaguanine, 7-deazaadenine, 7-aza-2,6-diaminopurine, 8-aza-7-deazaguanine, 8-aza-7-deazaadenine, 8-aza-7-deaza-2,6-diaminopurine, Super G, Super A, and N4-ethylcytosine, or derivatives thereof; 2 -Cyclopentylguanine (cPent-G), N 2 -cyclopentyl-2-aminopurine (cPent-AP), and N 22-propyl-2-aminopurine (Pr-AP), pseudouracil, or derivatives thereof; and degenerate or universal bases such as 2,6-difluorotoluene, or non-existent bases such as abasic sites (e.g., 1-deoxyribose, 1,2-dideoxyribose, 1-deoxy-2-O-methylribose; or pyrrolidine derivatives with the ring oxygen replaced by nitrogen (azaribose)). Examples of Super A, Super G, and Super T derivatives can be found in U.S. Patent No. 6,683,173 (Epoch Biosciences), which is incorporated herein by reference in its entirety. cPent-G, cPent-AP, and Pr-AP have been shown to reduce immunostimulatory effects when incorporated into siRNA (Peacock H. et al. J. Am. Chem. Soc. 2011, 133, 9200). Pseudouracil is a naturally occurring isomerized version of uracil, with the C-glycoside rather than the usual N-glycoside in uridine. Pseudouridine-containing synthetic mRNAs may have an improved safety profile compared to uridine-containing mPvNAs (WO2009127230, incorporated herein by reference in its entirety).

[0236] Certain nucleobases are particularly useful for increasing the binding affinity of the antisense oligomers or antisense oligomer conjugates of the present disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C, and are currently the more preferred base substitutions, particularly when combined with 2'-O-methoxyethyl sugar modifications. Additional exemplary modified nucleobases include those in which at least one hydrogen atom of the nucleobase is replaced with fluorine.

[0237] 11. Pharmaceutically acceptable salts of the antisense oligomer conjugates Certain embodiments of the antisense oligomer and antisense oligomer conjugate described herein may contain basic functional groups such as amino or alkylamino, and therefore can form pharmaceutically acceptable salts with pharmaceutically acceptable acids.The term "pharmaceutically acceptable salts" in this respect refers to the relatively non-toxic inorganic and organic acid addition salts of the antisense oligomer or antisense oligomer conjugate of the present disclosure.These salts can be prepared in situ during the administration vehicle or dosage form manufacturing process, or by separately reacting the purified antisense oligomer or antisense oligomer conjugate of the present disclosure in its free base form with a suitable organic or inorganic acid, and then isolating the salt thus formed during subsequent purification. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate (see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).

[0238] The pharma- ceutically acceptable salts of the subject antisense oligomer or antisense oligomer conjugate include, for example, the conventional non-toxic salts or quaternary ammonium salts of antisense oligomer or antisense oligomer conjugate from non-toxic organic or inorganic acids.For example, such conventional non-toxic salts include those derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, etc.; and the salts prepared from organic acids, such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid (salicyclic), sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isothionic acid, etc.

[0239] In certain embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure may contain one or more acidic functional groups, and therefore can form pharmaceutically acceptable salts with pharmaceutically acceptable bases.In these cases, the term "pharmaceutically acceptable salts" refers to the relatively non-toxic inorganic and organic base addition salts of the antisense oligomer or antisense oligomer conjugate of the present disclosure.These salts can also be prepared in situ during the administration vehicle or dosage form manufacturing process, or can be prepared by separately reacting the purified antisense oligomer or antisense oligomer conjugate in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine.Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. (See, for example, Berge et al., supra).

[0240] III. Formulations and Modes of Administration In certain embodiments, the present disclosure provides a formulation or pharmaceutical composition suitable for therapeutic delivery of the antisense oligomer or antisense oligomer conjugate described herein.Thus, in certain embodiments, the present disclosure provides a pharma- ceutically acceptable composition comprising a therapeutically effective amount of one or more of the antisense oligomer or antisense oligomer conjugate described herein, formulated with one or more pharma- ceutically acceptable carriers (additives) and / or diluents.Although it is possible to administer the antisense oligomer or antisense oligomer conjugate of the present disclosure alone, it is preferred to administer the antisense oligomer or antisense oligomer conjugate as a pharmaceutical formulation (composition).In one embodiment, the antisense oligomer or antisense oligomer conjugate of the formulation is according to formula (III):

[0241] Methods for delivery of nucleic acid molecules that are applicable to the antisense oligomers or antisense oligomer conjugates of the present disclosure are described, for example, in Akhtar et al., 1992, Trends Cell Bio., 2:139; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. A Akhtar, 1995, CRC Press, and Sullivan et al., PCT WO94 / 02595. These and other protocols can be utilized for delivery of virtually any nucleic acid molecule, including the antisense oligomers and antisense oligomer conjugates of the present disclosure.

[0242] The pharmaceutical compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for: (1) oral administration, e.g., as an immersion (aqueous or non-aqueous solution or suspension), tablet (for buccal, sublingual, or systemic absorption), bolus, powder, granule, paste for application to the tongue; (2) parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, epidural injection, e.g., as a sterile solution or suspension or sustained release formulation; (3) topical application, e.g., as a cream, ointment, or controlled release patch or spray applied to the skin; (4) intravaginally or rectally, e.g., as a pessary, cream, or foam; (5) sublingually; (6) intraocularly; (7) transdermally; or (8) intranasally.

[0243] Some examples of materials which can serve as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as protease, glycerol, sorbitol ... Examples of suitable non-toxic, compatible materials include, but are not limited to, pyrene glycol, (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol, (12) esters, such as ethyl oleate and ethyl laurate, (13) agar, (14) buffers, such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) pyrogen-free distilled water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) pH buffers, (21) polyesters, polycarbonates, and / or polyanhydrides, and (22) other non-toxic, compatible materials used in pharmaceutical formulations.

[0244] Additional non-limiting examples of agents suitable for formulation with the antisense oligomers or antisense oligomer conjugates of the present disclosure include PEG-conjugated nucleic acids; phospholipid-conjugated nucleic acids; nucleic acids containing lipophilic moieties; phosphorothioates; P-glycoprotein inhibitors (such as Pluronic P85) that can enhance drug entry into various tissues: biodegradable polymers, such as poly(D,L-lactide-coglycolide) microspheres for sustained delivery after implantation (Emerich, DF et al., 1999, Cell Transplant, 8, 47-58) Alkermes, Inc. Cambridge, Mass.; and loaded nanoparticles, such as those made of polybutyl cyanoacrylate, which can deliver drugs across the blood-brain barrier and alter neuronal uptake mechanisms (Prog Neuropsychopharmacol Biol Psychiatry, 23, 941-949, 1999).

[0245] The present disclosure also features the use of compositions that include surface-modified liposomes that contain poly(ethylene glycol) ("PEG") lipids (PEG-modified, branched, and non-branched, or combinations thereof, or long-circulating or stealth liposomes). The antisense oligomers and antisense oligomer conjugates of the present disclosure can also include covalently attached PEG molecules of various molecular weights. These formulations provide a method for increasing drug accumulation in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear cell phagocytic system (MPS or RES), thereby allowing for extended blood circulation time and enhanced tissue exposure of encapsulated drugs (Lasic et al. Chem. Rev. 1995, 95, 2601-2627; Ishiwata et al., Chem. Pharm. Bull. 1995, 43, 1005-1011). Such liposomes have been shown to selectively accumulate in tumors, possibly by extravasation and entrapment in vascularized target tissues (Lasic et al., Science 1995, 267, 1275-1276; Oku et al., 1995, Biochim. Biophys. Acta, 1238, 86-90). Long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, especially compared to conventional cationic liposomes, which are known to accumulate in tissues of MPS (Liu et al., J. Biol. Chem. 1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO96 / 10391; Ansell et al., International PCT Publication No. WO96 / 10390; Holland et al., International PCT Publication No. WO96 / 10392). Long-circulating liposomes also likely protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

[0246] In further embodiments, the present disclosure includes antisense oligomer pharmaceutical compositions and antisense oligomer conjugate pharmaceutical compositions prepared for delivery, as described in U.S. Patent Nos. 6,692,911, 7,163,695, and 7,070,807.In this regard, in one embodiment, the present disclosure provides the antisense oligomer or antisense oligomer conjugate of the present disclosure in a composition comprising a copolymer of lysine and histidine (HK) (described in U.S. Patent Nos. 7,163,695, 7,070,807, and 6,692,911), either alone or in combination with PEG (e.g., branched or unbranched PEG, or a mixture of both), in combination with PEG and a targeting moiety, or in combination with a crosslinking agent. In certain embodiments, the present disclosure provides an antisense oligomer or antisense oligomer conjugate in pharmaceutical composition that comprises gluconate-modified polyhistidine or gluconyl polyhistidine / transferrin-polylysine.Those skilled in the art will also recognize that amino acids with similar properties to His and Lys can be substituted in the composition.

[0247] Wetting agents, emulsifying agents, and lubricants (such as sodium lauryl sulfate and magnesium stearate), coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, and antioxidants can also be present in the composition.

[0248] Examples of pharma- ceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0249] The formulations of the present disclosure include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will vary depending on the subject being treated and the particular mode of administration. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will generally be that amount of active ingredient that produces a therapeutic effect. Generally, this amount will range from about 0.1 percent to about 99 percent of the active ingredient, preferably from about 5 percent to about 70 percent, and most preferably from about 10 percent to about 30 percent.

[0250] In certain embodiments, the formulation of the present disclosure comprises an excipient selected from cyclodextrin, cellulose, liposome, micelle-forming agent, such as bile acid, and polymer carrier, such as polyester and polyanhydride, and an antisense oligomer or antisense oligomer conjugate of the present disclosure.In one embodiment, the antisense oligomer or antisense oligomer conjugate of the formulation is according to formula (V) or formula (III), respectively.In certain embodiments, the above formulation makes the antisense oligomer or antisense oligomer conjugate of the present disclosure orally bioavailable.

[0251] Methods of preparing these formulations or pharmaceutical compositions include the step of bringing into association the antisense oligomer or antisense oligomer conjugate of the present disclosure with a carrier, and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the antisense oligomer or antisense oligomer conjugate of the present disclosure with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0252] Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with a flavored base, usually sucrose and acacia or tragacanth), powder, granules, or as a solution or suspension in an aqueous or non-aqueous solution, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a pastille (with an inert base, e.g., gelatin and glycerin, or sucrose and acacia) and / or as a mouthwash, each containing a predetermined amount of an antisense oligomer or antisense oligomer conjugate of the disclosure as an active ingredient. The antisense oligomer or antisense oligomer conjugate of the disclosure may also be administered as a bolus, electuary, or paste.

[0253] In solid dosage forms of the present disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches, etc.), the active ingredient may be mixed with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates. , and sodium carbonate, (5) dissolution retarders, such as paraffin, (6) absorption enhancers, such as quaternary ammonium compounds and surfactants, such as poloxamers and sodium lauryl sulfate, (7) wetting agents, such as cetyl alcohol, glycerol monostearate, nonionic surfactants, (8) absorbents, such as kaolin and bentonite clay, (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof, (10) coloring agents, and (11) release controlling agents, such as crospovidone or ethylcellulose. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also include buffering agents. Solid pharmaceutical compositions of a similar type may also be employed as fillers in soft and hard shell gelatin capsules, using such excipients as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0254] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents or dispersants. Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.

[0255] Tablets and other solid dosage forms of the pharmaceutical composition of the present disclosure, such as dragees, capsules, pills, and granules, can be obtained or prepared with optional coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can also be formulated to provide slow or controlled release of the active ingredient therein, for example, using hydroxypropylmethylcellulose in various proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They can also be formulated for rapid release, for example, lyophilization. They can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid pharmaceutical composition that can be dissolved in sterile water immediately before use, or some other sterile injectable medium. These pharmaceutical compositions can also optionally contain opacifying agents, and can have compositions that release the active ingredient(s) only, or preferentially, in a certain part of the digestive tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0256] The liquid dosage form for oral administration of the antisense oligomer or antisense oligomer conjugate of the present disclosure includes pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.In addition to active ingredients, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.

[0257] Besides inert diluents, the oral pharmaceutical compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

[0258] In addition to the active compounds, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

[0259] Formulations for rectal or vaginal administration may be presented as suppositories, which can be prepared by mixing one or more compounds of the present disclosure with one or more suitable non-irritating excipients or carriers including, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, which are solid at room temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active compound.

[0260] The preparation or dosage form for topical or transdermal administration of oligomers provided herein includes powder, spray, ointment, paste, cream, lotion, gel, solution, patch, and inhalant.Active antisense oligomer and antisense oligomer conjugate can be mixed with pharmaceutically acceptable carrier under sterile conditions, and with any preservative, buffer, or propellant that may be required.Ointment, paste, cream, and gel can contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof, in addition to the active compound of the present disclosure.

[0261] Powders and sprays can contain, in addition to the antisense oligomer or antisense oligomer conjugate of the present disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. Sprays can further contain customary propellants, such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons, such as butane and propane.

[0262] Transdermal patch has the additional advantage of providing controlled delivery of the antisense oligomer or antisense oligomer conjugate of the present disclosure into the body.Such dosage forms can be made by dissolving or dispersing the oligomer in suitable medium.Absorption enhancers can also be used to increase the flux of drug across the skin.The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the drug in a polymer matrix or gel, among other methods known in the art.

[0263] Pharmaceutical compositions suitable for parenteral administration may comprise one or more antisense oligomers or antisense oligomer conjugates of the present disclosure in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted immediately before use into sterile injectable solutions or dispersions, which may contain sugars, alcohols, antioxidants, buffers, bacteriostatic agents, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents. Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. In one embodiment, the antisense oligomer or antisense oligomer conjugate of the pharmaceutical composition is according to formula (V) or formula (III), respectively.

[0264] These pharmaceutical compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers, and dispersing agents. Prevention of microbial action on the subject antisense oligomer or antisense oligomer conjugates can be ensured by including various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the composition. In addition, sustained absorption of the injectable dosage form can be brought about by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0265] In some cases, it is desirable to delay the absorption of drugs from subcutaneous or intramuscular injection in order to prolong the effect of drugs.This can be achieved by using liquid suspension of crystalline or amorphous material with poor water solubility, among other methods known in the art.The absorption rate of drug then depends on its dissolution rate, which may depend on crystal size and crystalline form.Alternatively, the delayed absorption of parenterally administered drug forms can be achieved by dissolving or suspending the drug in oil vehicle.

[0266] Injectable depot forms can be made by forming microencapsule matrices of the subject antisense oligomer or antisense oligomer conjugate in biodegradable polymers such as polylactide-polyglycolide.Depending on the ratio of oligomer to polymer and the nature of the particular polymer used, the rate of oligomer release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).Depot injectable preparations can also be prepared by encapsulating the drug in liposomes or microemulsions that are compatible with body tissues.

[0267] When the antisense oligomers or antisense oligomer conjugates of the present disclosure are administered as pharmaceuticals to humans and animals, they may be administered per se or as a pharmaceutical composition containing, for example, 0.1-99% (more preferably 10-30%) of the antisense oligomer or antisense oligomer conjugate in combination with a pharma- ceutically acceptable carrier.

[0268] The formulation or preparation of the present disclosure can be administered orally, parenterally, topically or rectally.They are typically administered in a form suitable for each administration route.For example, they are administered in tablets or capsules, by injection, inhalation, eye lotion, ointment, suppository or infusion, topically by lotion or ointment, or rectally by suppository.

[0269] Regardless of the route of administration selected, the antisense oligomers and antisense oligomer conjugates of the present disclosure, which may be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present disclosure, may be formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those skilled in the art. The actual dosage level of the active ingredient in the pharmaceutical compositions of the present disclosure may vary to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without unacceptable toxicity to the patient.

[0270] The selected dosage level will depend on a variety of factors, including the activity of the particular antisense oligomer or antisense oligomer conjugate of the present disclosure, or ester, salt, or amide thereof, being employed, the route of administration, the time of administration, the rate of excretion or metabolism of the particular oligomer being employed, the rate and extent of absorption, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular oligomer being employed, the age, sex, weight, condition, general health, and medical history of the patient being treated, and similar factors well known in the medical art.

[0271] A physician or veterinarian of ordinary skill in the art can easily determine and prescribe the effective amount of pharmaceutical composition required. For example, a physician or veterinarian can start the dosage of the antisense oligomer or antisense oligomer conjugate of the present disclosure used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Generally, a suitable daily dose of the antisense oligomer or antisense oligomer conjugate of the present disclosure is the amount of the antisense oligomer or antisense oligomer conjugate that is the lowest dose effective to produce a therapeutic effect. Such effective doses generally depend on the factors described herein. Generally, oral, intravenous, intracerebroventricular, and subcutaneous doses of the antisense oligomer or antisense oligomer conjugate of the present disclosure for a patient range from about 0.0001 to about 100 mg per kilogram of body weight per day when used for the indicated effect.

[0272] In some embodiments, the antisense oligomers and antisense oligomer conjugates of the present disclosure are generally administered at a dose of about 10-160 mg / kg or 20-160 mg / kg. In some cases, a dose of more than 160 mg / kg may be necessary. In some embodiments, the intravenous dose is about 0.5 mg-160 mg / kg. In some embodiments, the antisense oligomer or antisense oligomer conjugate is administered at a dose of about 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg. In some embodiments, the antisense oligomer or antisense oligomer conjugate is administered at or near 10 mg / kg, 11 mg / kg, 12 mg / kg, 15 mg / kg, 18 mg / kg, 20 mg / kg, 21 mg / kg, 25 mg / kg, 26 mg / kg, 27 mg / kg, 28 mg / kg, 29 mg / kg, 30 mg / kg, 31 mg / kg, 32 mg / kg, 33 mg / kg, 34 mg / kg, 35 mg / kg, 36 mg / kg, 37 mg / kg, 38 mg / kg, 39 mg / kg, 40 mg / kg, 41 mg / kg, 42 mg / kg, 43 mg / kg, 44 mg / kg, 45 mg / kg, 46 mg / kg, 47 mg / kg, 48 mg / kg, 49 mg / kg, 50 mg / kg, 51 mg / kg, 52 mg / kg, 53 mg / kg, 54 mg / kg, 55 mg / kg, 56 mg / kg, 57 mg / kg, 58 mg / kg, 59 mg / kg, 60 mg / kg, 61 mg / kg, 62 mg / kg, 63 mg / kg, 64 mg / kg, 65 mg / kg, 66 mg / kg, 67 mg / kg, 68 mg / kg, 69 mg / kg, 70 mg / kg, 71 mg / kg, 72 mg / kg, 73 mg / kg, 74 mg / kg, 75 mg / kg, 76 mg / kg, 77 mg / kg, 78 mg / kg, 79 mg / kg, 80 mg / kg, 81 mg / kg, 82 mg / kg, 83 mg / kg, 84 mg / kg, 85 mg / kg, 86 mg / kg, 87 mg / kg g, 49 mg / kg, 50 mg / kg, 51 mg / kg, 52 mg / kg, 53 mg / kg, 54 mg / kg, 55 mg / kg, 56 mg / kg, 57 mg / kg, 58 mg / kg, 59 mg / kg, 60 mg / kg, 65 mg / kg, 70 mg / kg, 75 mg / kg, 80 mg / kg, 85 mg / kg, 90 mg / kg, 95 mg / kg, 100 mg / kg, 105 mg / kg, 110 mg / kg, 115 mg / kg, 120 mg / kg, 125 mg / kg, 130 mg / kg, 135 mg / kg, 140 mg / kg, 145 mg / kg, 150 mg / kg, 155 mg / kg, 160 mg / kg (including all integers therebetween). In some embodiments, the oligomer is administered at 10 mg / kg. In some embodiments, the oligomer is administered at 20 mg / kg.In some embodiments, the oligomer is administered at 30 mg / kg. In some embodiments, the oligomer is administered at 40 mg / kg. In some embodiments, the oligomer is administered at 60 mg / kg. In some embodiments, the oligomer is administered at 80 mg / kg. In some embodiments, the oligomer is administered at 160 mg / kg. In some embodiments, the oligomer is administered at 50 mg / kg.

[0273] In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is generally administered at a dose of about 10-160 mg / kg or 20-160 mg / kg. In some embodiments, the dose of the antisense oligomer conjugate of formula (III) for intravenous administration is about 0.5 mg-160 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at a dose of about 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg. In some embodiments, the antisense oligomer conjugate of Formula (III) or the antisense oligomer of Formula (V) is administered at a concentration of about 10 mg / kg, 11 mg / kg, 12 mg / kg, 15 mg / kg, 18 mg / kg, 20 mg / kg, 21 mg / kg, 25 mg / kg, 26 mg / kg, 27 mg / kg, 28 mg / kg, 29 mg / kg, 30 mg / kg, 31 mg / kg, 32 mg / kg, 33 mg / kg, 34 mg / kg, 35 mg / kg, 36 mg / kg, 37 mg / kg, 38 mg / kg, 39 mg / kg, 40 mg / kg, 41 mg / kg, 42 mg / kg, 43 mg / kg, 44 mg / kg, 45 mg / kg, 46 mg / kg, 47 mg / kg, and administered at doses of 48 mg / kg, 49 mg / kg, 50 mg / kg, 51 mg / kg, 52 mg / kg, 53 mg / kg, 54 mg / kg, 55 mg / kg, 56 mg / kg, 57 mg / kg, 58 mg / kg, 59 mg / kg, 60 mg / kg, 65 mg / kg, 70 mg / kg, 75 mg / kg, 80 mg / kg, 85 mg / kg, 90 mg / kg, 95 mg / kg, 100 mg / kg, 105 mg / kg, 110 mg / kg, 115 mg / kg, 120 mg / kg, 125 mg / kg, 130 mg / kg, 135 mg / kg, 140 mg / kg, 145 mg / kg, 150 mg / kg, 155 mg / kg, 160 mg / kg (including all integers therebetween).In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 10 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 20 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 30 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 40 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 60 mg / kg. In some embodiments, the antisense oligomer conjugate of formula (III) or the antisense oligomer of formula (V) is administered at 80 mg / kg. In some embodiments, the antisense oligomer conjugate of Formula (III) or the antisense oligomer of Formula (V) is administered at 160 mg / kg. In some embodiments, the antisense oligomer conjugate of Formula (III) or the antisense oligomer of Formula (V) is administered at 50 mg / kg.

[0274] If necessary, the effective daily dose of active compound may be administered as 2, 3, 4, 5, 6 or more partial doses, which are administered separately at appropriate intervals throughout the day, optionally in unit dosage form. In certain circumstances, the dosage is administered once a day. In certain embodiments, the dosage is administered once or more every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, or once or more every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks, or once or more every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, as necessary to maintain the desired expression of functional dystrophin protein. In certain embodiments, the dosage is administered once or more every two weeks. In some embodiments, the dosage is administered once every two weeks. In various embodiments, the dosage is administered once or more every month. In certain embodiments, the dosage is administered once a month.

[0275] In various embodiments, the antisense oligomer conjugate is administered at 10 mg / kg weekly. In various embodiments, the antisense oligomer conjugate is administered at 20 mg / kg weekly. In various embodiments, the antisense oligomer conjugate is administered at 30 mg / kg weekly. In various embodiments, the antisense oligomer conjugate is administered at 40 mg / kg weekly. In some embodiments, the antisense oligomer conjugate is administered at 60 mg / kg weekly. In some embodiments, the antisense oligomer conjugate is administered at 80 mg / kg weekly. In some embodiments, the antisense oligomer conjugate is administered at 100 mg / kg weekly. In some embodiments, the antisense oligomer conjugate is administered at 160 mg / kg weekly. As used herein, weekly is understood to have the art-accepted meaning of once a week.

[0276] In various embodiments, the antisense oligomer is administered weekly at 10 mg / kg. In various embodiments, the antisense oligomer is administered weekly at 20 mg / kg. In various embodiments, the antisense oligomer is administered weekly at 30 mg / kg. In various embodiments, the antisense oligomer is administered weekly at 40 mg / kg. In some embodiments, the antisense oligomer is administered weekly at 60 mg / kg. In some embodiments, the antisense oligomer is administered weekly at 80 mg / kg. In some embodiments, the antisense oligomer is administered weekly at 100 mg / kg. In some embodiments, the antisense oligomer is administered weekly at 160 mg / kg. As used herein, weekly is understood to have the art-accepted meaning of once a week.

[0277] In various embodiments, the antisense oligomer conjugate is administered at 10 mg / kg every other week. In various embodiments, the antisense oligomer conjugate is administered at 20 mg / kg every other week. In various embodiments, the antisense oligomer conjugate is administered at 30 mg / kg every other week. In various embodiments, the antisense oligomer conjugate is administered at 40 mg / kg every other week. In some embodiments, the antisense oligomer conjugate is administered at 60 mg / kg every other week. In some embodiments, the antisense oligomer conjugate is administered at 80 mg / kg every other week. In some embodiments, the antisense oligomer conjugate is administered at 100 mg / kg every other week. In some embodiments, the antisense oligomer conjugate is administered at 160 mg / kg every other week. As used herein, every other week is understood to have the art-accepted meaning of every two weeks.

[0278] In various embodiments, the antisense oligomer is administered at 10 mg / kg every other week. In various embodiments, the antisense oligomer is administered at 20 mg / kg every other week. In various embodiments, the antisense oligomer is administered at 30 mg / kg every other week. In various embodiments, the antisense oligomer is administered at 40 mg / kg every other week. In some embodiments, the antisense oligomer is administered at 60 mg / kg every other week. In some embodiments, the antisense oligomer is administered at 80 mg / kg every other week. In some embodiments, the antisense oligomer is administered at 100 mg / kg every other week. In some embodiments, the antisense oligomer is administered at 160 mg / kg every other week. As used herein, every other week is understood to have the art-accepted meaning of every two weeks.

[0279] In various embodiments, the antisense oligomer conjugate is administered at 10 mg / kg every three weeks. In various embodiments, the antisense oligomer conjugate is administered at 20 mg / kg every three weeks. In various embodiments, the antisense oligomer conjugate is administered at 30 mg / kg every three weeks. In various embodiments, the antisense oligomer conjugate is administered at 40 mg / kg every three weeks. In some embodiments, the antisense oligomer conjugate is administered at 60 mg / kg every three weeks. In some embodiments, the antisense oligomer conjugate is administered at 80 mg / kg every three weeks. In some embodiments, the antisense oligomer conjugate is administered at 100 mg / kg every three weeks. In some embodiments, the antisense oligomer conjugate is administered at 160 mg / kg every three weeks. As used herein, every three weeks is understood to have the art-accepted meaning of once every three weeks.

[0280] In various embodiments, the antisense oligomer is administered at 10 mg / kg every three weeks. In various embodiments, the antisense oligomer is administered at 20 mg / kg every three weeks. In various embodiments, the antisense oligomer is administered at 30 mg / kg every three weeks. In various embodiments, the antisense oligomer is administered at 40 mg / kg every three weeks. In some embodiments, the antisense oligomer is administered at 60 mg / kg every three weeks. In some embodiments, the antisense oligomer is administered at 80 mg / kg every three weeks. In some embodiments, the antisense oligomer is administered at 100 mg / kg every three weeks. In some embodiments, the antisense oligomer is administered at 160 mg / kg every three weeks. As used herein, every three weeks is understood to have the art-accepted meaning of once every three weeks.

[0281] In various embodiments, the antisense oligomer conjugate is administered at 10 mg / kg monthly. In various embodiments, the antisense oligomer conjugate is administered at 20 mg / kg monthly. In various embodiments, the antisense oligomer conjugate is administered at 30 mg / kg monthly. In various embodiments, the antisense oligomer conjugate is administered at 40 mg / kg monthly. In some embodiments, the antisense oligomer conjugate is administered at 60 mg / kg monthly. In some embodiments, the antisense oligomer conjugate is administered at 80 mg / kg monthly. In some embodiments, the antisense oligomer conjugate is administered at 100 mg / kg monthly. In some embodiments, the antisense oligomer conjugate is administered at 160 mg / kg monthly. As used herein, monthly is understood to have the art-accepted meaning of monthly.

[0282] In various embodiments, the antisense oligomer is administered monthly at 10 mg / kg. In various embodiments, the antisense oligomer is administered monthly at 20 mg / kg. In various embodiments, the antisense oligomer is administered monthly at 30 mg / kg. In various embodiments, the antisense oligomer is administered monthly at 40 mg / kg. In some embodiments, the antisense oligomer is administered monthly at 60 mg / kg. In some embodiments, the antisense oligomer is administered monthly at 80 mg / kg. In some embodiments, the antisense oligomer is administered monthly at 100 mg / kg. In some embodiments, the antisense oligomer is administered monthly at 160 mg / kg. As used herein, monthly is understood to have the art-accepted meaning of monthly.

[0283] As is understood in the art, weekly, biweekly, triweekly, or monthly administration may be one or more administrations or sub-doses as discussed herein.

[0284] The nucleic acid molecules, antisense oligomers, and antisense oligomer conjugates described herein can be administered to cells by various methods known to those skilled in the art, including, but not limited to, encapsulation in liposomes, iontophoresis, or incorporation into other vehicles such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, as described herein and known in the art. In certain embodiments, microemulsification technology may be utilized to improve the bioavailability of lipophilic (water-insoluble) pharmaceuticals. Examples include Trimetrine (Dordunoo, SK, et al., Drug Development and Industrial Pharmacy, 17(12), 1685-1713, 1991), and REV 5901 (Sheen, PC, et al., J Pharm Sci 80(7), 712-714, 1991). Among other advantages, microemulsification provides enhanced bioavailability by preferentially directing absorption into the lymphatic system instead of the circulatory system, thereby bypassing the liver and preventing destruction of compounds in the hepatobiliary circulation.

[0285] In one aspect of the disclosure, the formulation contains micelles formed from the oligomers provided herein and at least one amphiphilic carrier, wherein the micelles have an average diameter of less than about 100 nm. More preferred embodiments provide micelles having an average diameter of less than about 50 nm, and even more preferred embodiments provide micelles having an average diameter of less than about 30 nm or even less than about 20 nm.

[0286] Although all suitable amphiphilic carriers are contemplated, currently preferred carriers are generally those that have a generally recognized as safe (GRAS) status and can both solubilize the antisense oligomer or antisense oligomer conjugate of the present disclosure and microemulsify at a later stage when the solution comes into contact with a complex aqueous phase (such as that found in the human gastrointestinal tract). Amphiphilic components that meet these requirements typically have an HLB (hydrophilic-lipophilic balance) value of 2-20, and their structures contain straight-chain aliphatic radicals ranging from C-6 to C-20. Examples include polyethylene glycolated fatty acid glycerides and polyethylene glycols.

[0287] Examples of amphiphilic carriers include saturated and monounsaturated polyethylene glycolated fatty acid glycerides, such as those obtained from various fully or partially hydrogenated vegetable oils. Such oils may advantageously consist of tri-, di-, and mono-fatty acid glycerides, as well as di- and mono-poly(ethylene glycol) esters of the corresponding fatty acids, with particularly preferred fatty acid compositions including 4-10% capric acid, 3-9% capric acid, 40-50% lauric acid, 14-24% myristic acid, 4-14% palmitic acid, and 5-15% stearic acid. Another useful class of amphiphilic carriers includes partially esterified sorbitan and / or sorbitol with saturated or monounsaturated fatty acids (SPAN® series) or the corresponding ethoxylated analogues (TWEEN® series).

[0288] Commercially available amphiphilic carriers, including the Gelucire series, Labrafil, Labrasol, or Lauroglycol (all manufactured and distributed by Gattefosse Corporation, Saint Priest, France), PEG-mono-oleate, PEG-di-oleate, PEG-mono- and di-laurate, lecithin, polysorbate 80, and the like (manufactured and distributed by a number of companies in the United States and around the world), may be particularly useful.

[0289] In certain embodiments, delivery may occur by using liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, etc., to introduce the pharmaceutical composition of the present disclosure into suitable host cells. In particular, the pharmaceutical composition of the present disclosure may be formulated for delivery encapsulated in either lipid particles, liposomes, vesicles, nanospheres, nanoparticles, or the like. The formulation and use of such delivery vehicles may be carried out using known and conventional techniques.

[0290] Hydrophilic polymers suitable for use in the present disclosure are those that are readily water-soluble, can be covalently attached to vesicle-forming lipids, and are tolerated in vivo without toxic effects (i.e., are biocompatible). Suitable polymers include poly(ethylene glycol) (PEG), polylactic acid (also called polylactide), polyglycolic acid (also called polyglycolide), polylactic acid-polyglycolic acid copolymers, and polyvinyl alcohol. In certain embodiments, the polymer has a weight average molecular weight of about 100 or 120 daltons up to about 5,000 or 10,000 daltons, or about 300 daltons to about 5,000 daltons. In other embodiments, the polymer is a poly(ethylene glycol) having a weight average molecular weight of about 100 to about 5,000 daltons, or having a weight average molecular weight of about 300 to about 5,000 daltons. In certain embodiments, the polymer is a poly(ethylene glycol) having a weight average molecular weight of about 750 daltons, e.g., PEG(750). A polymer may also be defined by the number of monomers therein; preferred embodiments of the present disclosure utilize polymers of at least about three monomers; such a PEG polymer consisting of three monomers has a molecular weight of about 132 daltons.

[0291] Other hydrophilic polymers that may be suitable for use in the present disclosure include polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethylcellulose.

[0292] In certain embodiments, the formulations of the present disclosure comprise a biocompatible polymer selected from the group consisting of polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides, polysiloxanes, polyurethanes and copolymers thereof, cellulose, polypropylene, polyethylene, polystyrene, polymers of lactic and glycolic acid, polyanhydrides, poly(ortho)esters, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), polysaccharides, proteins, polyhyaluronic acid, polycyanoacrylates, and blends, mixtures, or copolymers thereof.

[0293] Cyclodextrins are cyclic oligosaccharides consisting of 6, 7, or 8 glucose units, designated by the Greek letters α, β, or γ, respectively. The glucose units are linked by α-1,4-glucosidic bonds. As a result of the chair conformation of the sugar units, all the secondary hydroxyl groups (at C-2, C-3) are located on one side of the ring, while all the primary hydroxyl groups at C-6 are located on the other side. As a result, the exterior surface is hydrophilic, making cyclodextrins water-soluble. In contrast, the cavities of cyclodextrins are hydrophobic, since they are lined by hydrogens at atoms C-3 and C-5, and by ether-like oxygens. These matrices allow complexation with a variety of relatively hydrophobic compounds, including, for example, steroid compounds such as 17α-estradiol (see, for example, van Uden et al. Plant Cell Tiss. Org. Cult. 38:1-3-113 (1994)). Complexation occurs through van der Waals interactions and hydrogen bond formation. For a general review of the chemistry of cyclodextrins, see Wenz, Agnew. Chem. Int. Ed. Engl., 33:803-822 (1994).

[0294] The physicochemical properties of cyclodextrin derivatives depend largely on the type and degree of substitution. For example, their water solubility ranges from insoluble (e.g., triacetyl-beta-cyclodextrin) to 147% soluble (w / v) (G-2-beta-cyclodextrin). In addition, they are soluble in many organic solvents. The properties of cyclodextrins allow the control of the solubility of various formulation components by increasing or decreasing their solubility.

[0295] Numerous cyclodextrins and methods for their preparation have been described. For example, Parmeter (I) et al. (U.S. Pat. No. 3,453,259) and Gramera et al. (U.S. Pat. No. 3,459,731) have described electrically neutral cyclodextrins. Other derivatives include cyclodextrins with cationic character [Parmeter (II), U.S. Pat. No. 3,453,257], insoluble crosslinked cyclodextrins (Solms, U.S. Pat. No. 3,420,788), and cyclodextrins with anionic character [Parmeter (III), U.S. Pat. No. 3,426,011]. Among the cyclodextrin derivatives with anionic character, carboxylic acids, phosphorous acids, phosphinic acids, phosphonic acids, phosphoric acids, thiophosphonic acids, thiosulfinic acids, and sulfonic acids are added to the parent cyclodextrin [Parmeter (III), see above]. Additionally, sulfoalkyl ether cyclodextrin derivatives have been described by Stella et al. (US Pat. No. 5,134,127).

[0296] Liposomes consist of at least one lipid bilayer membrane surrounding an aqueous interior compartment. Liposomes can be characterized by membrane type and size. Small unilamellar vesicles (SUVs) have a single membrane and typically range from 0.02 to 0.05 μm in diameter, while large unilamellar vesicles (LUVS) are typically larger than 0.05 μm. Oligolamellar and multilamellar vesicles have multiple, usually concentric, membrane layers and are typically larger than 0.1 μm. Liposomes with several non-concentric membranes, i.e., several smaller vesicles contained within a larger vesicle, are called multivesicular vesicles.

[0297] One aspect of the present disclosure relates to a formulation comprising liposomes containing the antisense oligomer or antisense oligomer conjugate of the present disclosure, wherein the liposome membrane is formulated to provide liposomes with increased loading capacity.Alternatively or additionally, the antisense oligomer or antisense oligomer conjugate of the present disclosure may be contained within or adsorbed onto the liposome bilayer of the liposome.The antisense oligomer or antisense oligomer conjugate of the present disclosure may be aggregated with lipid surfactant and loaded into the inner space of the liposome.In these cases, the liposome membrane is formulated to resist the disruptive effect of active agent-surfactant aggregates.

[0298] According to one embodiment of the present disclosure, the lipid bilayer of the liposome contains lipids derivatized with poly(ethylene glycol) (PEG), such that PEG chains extend from the inner surface of the lipid bilayer into the interior space encapsulated by the liposome and extend from the exterior of the lipid bilayer into the surrounding environment.

[0299] The active agent contained within the liposomes of the present disclosure is in solubilized form. Aggregates of surfactant and active agent (such as emulsions or micelles containing the active agent of interest) may be entrapped within the interior space of liposomes according to the present disclosure. The surfactant acts to disperse and solubilize the active agent and may be selected from any suitable aliphatic, alicyclic, or aromatic surfactant, including but not limited to biocompatible lysophosphatidylcholines (LPGs) of various chain lengths (e.g., from about C14 to about C20). Polymer-derivatized lipids, such as PEG-lipids, may also be utilized for micelle formation, as they act to inhibit micelle / membrane fusion and the addition of polymers to the surfactant molecule reduces the CMC of the surfactant, aiding in micelle formation. Surfactants with CMOs in the micromolar range are preferred, and higher CMC surfactants may be utilized to prepare micelles entrapped within the liposomes of the present disclosure.

[0300] Liposomes according to the present disclosure can be prepared by any of a variety of techniques known in the art.See, for example, U.S. Patent No. 4,235,871, published PCT application WO96 / 14057, New RRC, Liposomes: A practical approach, IRL Press, Oxford (1990), pages 33-104, and Lasic DD, Liposomes from physics to applications, Elsevier Science Publishers BV, Amsterdam, 1993.For example, liposomes according to the present disclosure can be prepared by diffusing lipids derivatized with hydrophilic polymers into preformed liposomes, e.g., by exposing preformed liposomes to micelles composed of lipid-grafted polymers, at lipid concentrations corresponding to the final mole percent of the desired derivatized lipid in the liposome.Liposomes containing hydrophilic polymers can also be formed by homogenization, lipid field hydration, or extrusion techniques, as known in the art.

[0301] In another exemplary formulation procedure, active agent is first dispersed by sonication in lysophosphatidylcholine or other low CMC surfactants (including polymer-grafted lipids) that easily solubilize hydrophobic molecules.Then, the resulting micelle suspension of active agent is used to rehydrate the dried lipid sample that contains suitable mole percent of polymer-grafted lipids or cholesterol.Then, the lipid and active agent suspension is formed into liposomes using extrusion techniques known in the art, and the resulting liposomes are separated from the non-encapsulated solution by standard column separation.

[0302] In one aspect of the present disclosure, liposomes are prepared to have a substantially uniform size in a selected size range.One effective size determination method involves extruding an aqueous suspension of liposomes through a series of polycarbonate membranes with a selected uniform pore size, the pore size of the membrane roughly corresponding to the maximum size of the liposomes that will be produced by extrusion through the membrane.See, for example, U.S. Patent No. 4,737,323 (April 12, 1988).In certain embodiments, reagents such as DharmaFECT® and Lipofectamine® can be used to introduce polynucleotides or proteins into cells.

[0303] The release characteristics of the formulations of the present disclosure depend on the encapsulation material, the concentration of the encapsulated drug, and the presence of release modifiers. For example, release can be engineered to be pH dependent, for example, using a pH-sensitive coating that releases only at low pH, as found in the stomach, or high pH, ​​as found in the intestine. Enteric coatings can be used so that release does not occur until after passage through the stomach. Multiple coatings or mixtures of cyanamide encapsulated in different materials can be used to obtain an early release in the stomach followed by a later release in the intestine. Release can also be engineered by including salts or pore formers, which can increase water uptake or release of the drug by diffusion from the capsule. Excipients that modify the solubility of the drug can also be used to control the release rate. Agents that enhance the degradation of the matrix or release from the matrix can also be incorporated. They can be added to the drug, added as a separate phase (i.e., as particulates), or co-dissolved in the polymer phase depending on the compound. In most cases, the amount should be between 0.1 and 30 percent (w / w polymer). Types of degradation promoters include inorganic salts such as ammonium sulfate and ammonium chloride, organic acids such as citric acid, benzoic acid, and ascorbic acid, inorganic bases such as sodium carbonate, potassium carbonate, calcium carbonate, zinc carbonate, and zinc hydroxide, and organic bases such as protamine sulfate, spermine, choline, ethanolamine, diethanolamine, and triethanolamine, and surfactants such as Tween® and Pluronic®. Pore formers (i.e., water-soluble compounds such as inorganic salts and sugars) that add microstructure to the matrix are added as microparticles. The range is typically 1 to 30 percent (w / w polymer).

[0304] Uptake can also be manipulated by changing the residence time of the particle in the intestine.This can be achieved, for example, by coating the particle with a mucoadhesive polymer or by selecting it as the encapsulation material.Examples include most polymers with free carboxyl groups, such as chitosan, cellulose, and especially polyacrylates (as used herein, polyacrylates refers to polymers that contain acrylate groups and modified acrylate groups, such as cyanoacrylates and methacrylates).

[0305] Antisense oligomer or antisense oligomer conjugate can be formulated to be contained in or adapted to be released by surgical or medical devices or implants.In certain embodiments, implants can be coated or otherwise treated with antisense oligomer or antisense oligomer conjugate.For example, hydrogel or other polymers such as biocompatible and / or biodegradable polymers can be used to coat the implant with the pharmaceutical composition of the present disclosure (i.e., the composition can be adapted to be used with medical devices using hydrogel or other polymers).Polymers and copolymers for coating medical devices with drugs are well known in the art.Examples of implants include, but are not limited to, stents, drug-eluting stents, sutures, prostheses, vascular catheters, dialysis catheters, vascular grafts, artificial heart valves, cardiac pacemakers, implantable cardioverter defibrillators, IV needles, bone and osteogenic devices, such as pins, screws, plates, and other devices, and artificial tissue matrices for wound healing.

[0306] In addition to the methods provided herein, the antisense oligomers and antisense oligomer conjugates for use according to the present disclosure can be formulated for administration in any convenient manner for use in human or veterinary medicine, by analogy with other pharmaceuticals.The antisense oligomers and antisense oligomer conjugates and their corresponding formulations can be administered alone or in combination with other therapeutic strategies in the treatment of muscular dystrophy, such as myoblast transplantation, stem cell therapy, administration of aminoglycoside antibiotics, proteasome inhibitors, and upregulation therapy (e.g., upregulation of utrophin, the autosomal paralog of dystrophin).

[0307] In some embodiments, additional therapeutic agents may be administered prior to, simultaneously with, or after administration of the antisense oligomer or antisense oligomer conjugate of the present disclosure. For example, antisense oligomers and antisense oligomer conjugates may be administered in combination with steroids and / or antibiotics. In certain embodiments, antisense oligomers or antisense oligomer conjugates are administered to patients undergoing background steroid therapy (e.g., intermittent or long-term / continuous background steroid therapy). For example, in some embodiments, the patient has been treated with corticosteroids prior to administration of the antisense oligomer and continues to undergo steroid therapy. In some embodiments, the steroid is a glucocorticoid or prednisone.

[0308] The described routes of administration are intended as a guide only, as one skilled in the art can easily determine the optimal route of administration and any dosage for any particular animal and condition.Several approaches have been attempted to introduce functional new genetic material into cells, both in vitro and in vivo (Friedmann (1989) Science, 244:1275-1280). These approaches include incorporation of the gene to be expressed into modified retroviruses (Friedmann (1989) supra; Rosenberg (1991) Cancer Research 51(18), suppl.:5074S-5079S), into non-retroviral vectors (e.g., adeno-associated virus vectors) (Rosenfeld, et al. (1992) Cell, 68:143-155; Rosenfeld, et al. (1991) Science, 252:431-434), or delivery of the transgene linked to a heterologous promoter-enhancer element via liposomes (Friedmann (1989) supra; Brigham, et al. (1989) Am. J. Med. Sci., 298:278-281; ​​Nabel, et al. (1990) Science, 249:1285-1288; Hazinski, et al. al. (1991) Am. J. Resp. Cell Molec. Biol., 4:206-209, and Wang and Huang (1987) Proc. Natl. Acad. Sci. (USA), 84:7851-7855), ligand-specific, binding to cation transport systems (Wu and Wu (1988) J. Biol. Chem., 263:14621-14624), or using naked DNA, expression vectors (Nabel et al. (1990), supra; Wolff et al. (1990) Science, 247:1465-1468). Direct injection of a transgene into a tissue results in only local expression (Rosenfeld (1992) supra, Rosenfeld et al. (1991) supra, Brigham et al. (1989) supra, Nabel (1990) supra, and Hazinski et al. (1991) supra).The group of Brigham et al. (Am. J. Med. Sci. (1989) 298:278-281 and Clinical Research (1991) 39 (abstract)) has reported only in vivo transfection of mouse lungs after either intravenous or intratracheal administration of DNA-liposome complexes. An example of a review article on human gene therapy procedures is Anderson, Science (1992) 256:808-813.

[0309] In further embodiments, the pharmaceutical composition of the present disclosure may be co-administered with carbohydrates in the methods of the present disclosure, either in the same formulation or in a separate formulation, as provided in Han et al., Nat.Comms.7,10981 (2016), which is incorporated herein by reference in its entirety. In some embodiments, the pharmaceutical composition of the present disclosure may comprise 5% hexose carbohydrates. For example, the pharmaceutical composition of the present disclosure may comprise 5% glucose, 5% fructose, or 5% mannose. In certain embodiments, the pharmaceutical composition of the present disclosure may comprise 2.5% glucose and 2.5% fructose. In some embodiments, a pharmaceutical composition of the present disclosure may comprise carbohydrates selected from arabinose present in an amount of 5% by volume, glucose present in an amount of 5% by volume, sorbitol present in an amount of 5% by volume, galactose present in an amount of 5% by volume, fructose present in an amount of 5% by volume, xylitol present in an amount of 5% by volume, mannose present in an amount of 5% by volume, a combination of glucose and fructose each present in an amount of 2.5% by volume, and a combination of glucose present in an amount of 5.7% by volume, fructose present in an amount of 2.86% by volume, and xylitol present in an amount of 1.4% by volume.

[0310] IV. How to use Restoration of the dystrophin reading frame using exon skipping Potential therapeutic approach to treat DMD caused by out-of-frame mutation of dystrophin gene is suggested by milder type of dystrophinopathy known as BMD caused by in-frame mutation.The ability to convert out-of-frame mutation into in-frame mutation hypothetically maintains mRNA reading frame and produces internally truncated but functional dystrophin protein.The antisense oligomer and antisense oligomer conjugate of the present disclosure are designed to achieve this.

[0311] Hybridization of PMO with target pre-mRNA sequence prevents the formation of pre-mRNA splicing complex, and exon 53 is deleted from mature mRNA.The structure and conformation of the antisense oligomer and antisense oligomer conjugate of the present disclosure allow sequence-specific base pairing to complementary sequence.By a similar mechanism, for example, eteplirsen, a PMO designed to skip exon 51 of dystrophin pre-mRNA, allows sequence-specific base pairing to complementary sequence contained in exon 51 of dystrophin pre-mRNA.

[0312] Normal dystrophin mRNA containing all 79 exons produces normal dystrophin protein. The diagram in Figure 1 shows a small section of dystrophin pre-mRNA and mature mRNA from exon 47 to exon 53. The shape of each exon shows how the codons are split between exons. Notably, one codon consists of three nucleotides. Rectangular exons start and end with a complete codon. Arrow-shaped exons start with a complete codon but end with a split codon that contains only nucleotide #1 of the codon. Nucleotides #2 and #3 of this codon are contained in the subsequent exon that starts with a chevron shape.

[0313] Dystrophin mRNA that is missing an entire exon from the dystrophin gene typically results in DMD. The diagram in Figure 2 shows the type of genetic mutation (deletion of exon 50) known to result in DMD. Because exon 49 ends at a full codon and exon 51 begins at the second nucleotide of the codon, the reading frame after exon 49 is shifted, resulting in an out-of-frame mRNA reading frame and incorporation of an incorrect amino acid downstream of the mutation. An unstable dystrophin protein is then produced due to the absence of a functional C-terminal dystroglycan binding domain.

[0314] Eteplirsen restores the mRNA reading frame by skipping exon 51. Because exon 49 ends at a complete codon and exon 52 begins at the first nucleotide of the codon, deletion of exon 51 restores the reading frame and results in the production of an internally truncated dystrophin protein with an intact dystroglycan binding site, similar to the "in-frame" BMD mutation (Figure 3).

[0315] The feasibility of using exon skipping to restore the dystrophin mRNA open reading frame to ameliorate the DMD phenotype is supported by non-clinical studies. Many studies in dystrophic animal models of DMD have shown that restoring dystrophin by exon skipping results in robust improvements in muscle strength and function (Sharp 2011, Yokota 2009, Wu 2008, Wu 2011, Barton-Davis 1999, Goyenvalle 2004, Gregorevic 2006, Yue 2006, Welch 2007, Kawano 2008, Reay 2008, van Putten 2012). A compelling example of this comes from a study comparing dystrophin levels after exon skipping (with PMO) therapy to muscle function in the same tissue. In dystrophic mdx mice, tibialis anterior (TA) muscles treated with mouse-specific PMO maintained approximately 75% of their maximum tolerated force after stress-induced contraction, whereas untreated contralateral TA muscles maintained only approximately 25% of their maximum tolerated force (p<0.05) (Sharp 2011). In another study, three dystrophic CXMD dogs received exon skipping therapy using PMO specific for their gene mutation once a week for 5-7 weeks or every other week for 22 weeks at 2-5 months of age. After exon skipping therapy, all three dogs showed widespread systemic expression of dystrophin in skeletal muscle, as well as maintained or improved gait (15m running test) compared to baseline. In contrast, untreated age-matched CXMD dogs showed a significant decline in gait over the course of the study (Yokota 2009).

[0316] In both mdx mice expressing the entire human DMD transcript and in humanized DMD (hDMD) mouse models, PMO was shown to have more exon skipping activity at equimolar concentrations than phosphorothioate (Heemskirk 2009). In vitro experiments using reverse transcription polymerase chain reaction (RT-PCR) and Western blot (WB) in normal human skeletal muscle cells or muscle cells from DMD patients with different mutations amenable to exon 51 skipping identified eteplirsen (PMO) as a potent inducer of exon 51 skipping. Eteplirsen-induced exon 51 skipping has been confirmed in vivo in hDMD mouse models (Arechavala-Gomeza 2007).

[0317] Clinical outcomes to analyze the effect of antisense oligomers or antisense oligomer conjugates, which are complementary to the target region of exon 53 of human dystrophin pre-mRNA and induce exon 53 skipping, include percentage of dystrophin positive fibers (PDPF), 6-minute walk test (6MWT), loss of ambulation (LOA), North Star Ambulation Assessment (NSAA), pulmonary function tests (PFTs), ability to stand up (from supine position) without external support, de novo dystrophin production, and other functional measures.

[0318] In some embodiments, the present disclosure provides a method for producing dystrophin in a subject having a mutation in the dystrophin gene that is suitable for skipping exon 53, the method comprising administering to the subject an antisense oligomer conjugate or a pharma- ceutically acceptable salt thereof as described herein.In certain embodiments, the present disclosure provides a method for restoring the mRNA reading frame and inducing dystrophin protein production in a subject having Duchenne muscular dystrophy (DMD) having a mutation in the dystrophin gene that is suitable for skipping exon 53.Protein production can be measured by reverse transcription polymerase chain reaction (RT-PCR), Western blot analysis, or immunohistochemistry (IHC).

[0319] In some embodiments, the present disclosure provides a method for producing dystrophin in a subject having a mutation in the dystrophin gene that is suitable for skipping exon 53, the method comprising administering to the subject an antisense oligomer or a pharma- ceutically acceptable salt thereof as described herein.In certain embodiments, the present disclosure provides a method for restoring the mRNA reading frame and inducing dystrophin protein production in a subject having Duchenne muscular dystrophy (DMD) having a mutation in the dystrophin gene that is suitable for skipping exon 53.Protein production can be measured by reverse transcription polymerase chain reaction (RT-PCR), Western blot analysis, or immunohistochemistry (IHC).

[0320] In some embodiments, the disclosure provides a method for treating DMD in a subject in need thereof, wherein the subject has a mutation in the dystrophin gene that is amenable to skipping of exon 53, the method comprising administering to the subject an antisense oligomer conjugate, or a pharma- ceutically acceptable salt thereof, as described herein.

[0321] In some embodiments, the disclosure provides a method for treating DMD in a subject in need thereof, wherein the subject has a mutation in the dystrophin gene that is amenable to skipping of exon 53, the method comprising administering to the subject an antisense oligomer, or a pharma- ceutically acceptable salt thereof, as described herein.

[0322] In various embodiments, the treatment of the subject is measured by delaying disease progression.In some embodiments, the treatment of the subject is measured by maintaining the ambulation in the subject or reducing the ambulation in the subject.In some embodiments, the ambulation is measured using 6-minute walk test (6MWT).In certain embodiments, the ambulation is measured using North Start Ambulation Assessment (NSAA).

[0323] In some embodiments, the disclosure provides a method for maintaining lung function or reducing loss of lung function in a subject with DMD, wherein the subject has a mutation in the DMD gene that is amenable to skipping of exon 53, the method comprising administering to the subject an antisense oligomer conjugate, or a pharma- ceutically acceptable salt thereof, as described herein.

[0324] In some embodiments, the disclosure provides a method for maintaining lung function or reducing loss of lung function in a subject with DMD, wherein the subject has a mutation in the DMD gene that is amenable to skipping of exon 53, the method comprising administering to the subject an antisense oligomer, or a pharma- ceutical acceptable salt thereof, as described herein.

[0325] In some embodiments, pulmonary function is measured as maximum expiratory pressure (MEP). In certain embodiments, pulmonary function is measured as maximum inspiratory pressure (MIP). In some embodiments, pulmonary function is measured as forced vital capacity (FVC).

[0326] In further embodiments, the pharmaceutical composition of the present disclosure may be co-administered with carbohydrates in the methods of the present disclosure, either in the same formulation or in a separate formulation, as provided in Han et al., Nat.Comms.7,10981 (2016), which is incorporated herein by reference in its entirety. In some embodiments, the pharmaceutical composition of the present disclosure may be co-administered with 5% hexose carbohydrates. For example, the pharmaceutical composition of the present disclosure may be co-administered with 5% glucose, 5% fructose, or 5% mannose. In certain embodiments, the pharmaceutical composition of the present disclosure may be co-administered with 2.5% glucose and 2.5% fructose. In some embodiments, the pharmaceutical compositions of the present disclosure may be co-administered with a carbohydrate selected from arabinose present in an amount of 5% by volume, glucose present in an amount of 5% by volume, sorbitol present in an amount of 5% by volume, galactose present in an amount of 5% by volume, fructose present in an amount of 5% by volume, xylitol present in an amount of 5% by volume, mannose present in an amount of 5% by volume, a combination of glucose and fructose each present in an amount of 2.5% by volume, and a combination of glucose present in an amount of 5.7% by volume, fructose present in an amount of 2.86% by volume, and xylitol present in an amount of 1.4% by volume.

[0327] In various embodiments, the antisense oligomer or antisense oligomer conjugate of the present disclosure is co-administered with a therapeutically effective amount of a nonsteroidal anti-inflammatory compound. In some embodiments, the nonsteroidal anti-inflammatory compound is an NF-kB inhibitor. For example, in some embodiments, the NF-kB inhibitor may be CAT-1004 or a pharmaceutically acceptable salt thereof. In various embodiments, the NF-kB inhibitor may be a conjugate of salicylate and DHA. In some embodiments, the NF-kB inhibitor is CAT-1041 or a pharmaceutically acceptable salt thereof. In certain embodiments, the NF-kB inhibitor is a conjugate of salicylate and EPA. In various embodiments, the NF-kB inhibitor is [ka] or a pharma- ceutically acceptable salt thereof.

[0328] In some embodiments, the nonsteroidal anti-inflammatory compound is a TGF-b inhibitor. For example, in certain embodiments, the TGF-b inhibitor is HT-100.

[0329] In certain embodiments, the antisense oligomer or antisense oligomer conjugate described herein is described for use in therapy.In certain embodiments, the antisense oligomer or antisense oligomer conjugate described herein is described for use in the treatment of Duchenne muscular dystrophy.In certain embodiments, the antisense oligomer or antisense oligomer conjugate described herein is described for use in the manufacture of a medicament for use in therapy.In certain embodiments, the antisense oligomer or antisense oligomer conjugate described herein is described for use in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy.

[0330] V. kit The present disclosure also provides a kit for treating patients with genetic disease, which comprises at least an antisense molecule (e.g., the antisense oligomer or antisense oligomer conjugate described herein) packaged in a suitable container, together with instructions for its use. The kit may also include peripheral reagents such as buffers, stabilizers, etc. Those skilled in the art should understand that the application of the above method has broad applications to identify antisense molecules suitable for use in the treatment of many other diseases. In one embodiment, the kit comprises an antisense oligomer conjugate according to formula (III). In one embodiment, the kit comprises an antisense oligomer according to formula (V). EXAMPLES

[0331] Although the above disclosure has been described in some detail by way of illustration and examples for purposes of clarity of understanding, it will be readily apparent to those skilled in the art that, in light of the teachings of this disclosure, certain changes and modifications can be made thereto without departing from the spirit or scope of the appended claims. The following examples are provided by way of illustration only and are not limiting. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to produce substantially similar results.

[0332] material and method Cell and tissue culture treatment conditions Exon skipping was measured using differentiated human muscle cells (ZenBio, Inc.). Specifically, myoblast cells (ZenBio, Inc., SKB-F) were incubated in growth medium (SKB-M, ZenBio, Inc.) at 37°C and 5% CO. 2 The cells were grown to 80-90% confluence in 1×10 mM NaCl. Differentiation was initiated by replacing the growth medium with differentiation medium (SKM-D, ZenBio, Inc.). To assay exon 53 skipping, 1×10 4 Differentiated cells were seeded into 24-well plates, and 1 mL of differentiation medium (SKM-D, ZenBio, Inc.) containing various concentrations of PMO or PPMO was added to each well and incubated for 96 hours.

[0333] Western blot analysis For Western blot analysis, tissues were homogenized using homogenization buffer (4% SDS, 4 M urea, 125 mM Tris-HCl (pH 6.8)) in a ratio of 9-18 × 20 μm tissue sections with a diameter of approximately 5 mm in 133 μL of buffer. Corresponding lysates were taken and subjected to protein quantification using the RC DC Protein Assay Kit (BioRad catalog number 500-0122) according to the manufacturer's instructions. Tissue extract samples were diluted 1:10 using homogenization buffer to fall within the range of the BSA standard curve. Samples were prepared using 25 μl protein lysate, 7 μl NuPAGE LDS sample buffer (Life Technologies catalog number NP0008, Carlsbad, California, USA), and 3 μl NuPAGE reducing agent (10x) (Life Technologies catalog number NP0004) such that 35 μl sample contained the desired amount of protein. Protein samples were heated at 95°C for 5 minutes, after which the samples were centrifuged and the supernatants were loaded onto NuPAGE Novex 10-well, 1 mm, mini 3-8% polyacrylamide Tris-acetate gels (Life Technologies Catalog No. EA0375) with a maximum total protein loading of 50 μg per lane. Gels were run at 150 volts at room temperature until the dye front ran off the gel. The resulting protein gel was transferred to a PVDF membrane (Life Technologies Catalog No. LC2007) using NuPAGE transfer buffer (Life Technologies NP006-1), 10% methanol, and 0.1% NuPAGE antioxidant (Life Technologies NP0005) at 30 volts for 75 minutes at room temperature.

[0334] After protein transfer, the PVDF membrane was soaked in TTBS buffer (1X TBS (Amresco Cat. No. J640-4L), 0.1% (v / v) Tween®-20). The membrane was transferred to blocking buffer (5% (w / v) non-fat dry milk in TTBS (Lab Scientific Cat. No. M0841)) and soaked overnight at 4°C with gentle rocking. After blocking, the membrane was incubated either in DYS1 (Leica Cat. No. NCL-DYS1) diluted 1:20 using blocking buffer for 60 minutes at room temperature or in anti-α-actinin antibody (Sigma-Aldrich Cat. No. NA931V) diluted 1:100,000 in blocking buffer for 20 minutes at room temperature, followed by six washes (TTBS for 5 minutes each). Anti-mouse IgG conjugated to horseradish peroxidase (GE Healthcare Cat. No. NA931V) was diluted 1:40,000 using blocking buffer and added to the membrane for 45 min (DYS1) or 15 min (α-actinin), followed by washing again six times. Films were exposed to the gels using an ECL Prime Western Detection Kit (GE Healthcare Cat. No. RPN2232) and developed accordingly. The developed films were scanned and analyzed using ImageQuant TL Plus software (version 8.1) and linear regression analysis was performed using Graphpad software.

[0335] Each Western blot gel contains a four- or five-point dystrophin standard curve prepared using total protein extracted from normal tissues (mouse quadriceps, diaphragm, or heart) diluted to, for example, 64%, 16%, 4%, 1%, and 0.25% (see, for example, Figures 5A and 5B) and spiked into DMD tissue (e.g., mdx mouse quadriceps, diaphragm, or heart, or NHP quadriceps, diaphragm, or smooth muscle (GI)) extracts. Standard curve samples were processed as described above. Dystrophin protein levels as a percentage of wild-type dystrophin levels (%WT) were determined by comparing dystrophin band intensity to the gel standard curve.

[0336] RT-PCR analysis For RT-PCR analysis, RNA was isolated from cells using an Illustra GE spin kit according to the manufacturer's protocol. RNA concentration and purity were determined using a NanoDrop. Exon 53 skipping was measured by RT-PCR using a forward primer binding the exon 51 / 52 junction and 54 SEQ ID NO: 138 (5'-CATCAAGCAGAAGGCAACAA-3') and a reverse primer binding the exon 51 / 52 junction and 54 SEQ ID NO: 139 (5'-GAAGTTTCAGGGCCAAGTCA-3'). Skipped exon 53 gave rise to an amplicon of 201 bp, and non-skipped exon 53 gave rise to an amplicon of 413 bp. Skipping of mouse exon 23 was measured by RT-PCR using forward primer SEQ ID NO: 140 (5'-CACATCTTTGATGGTGTGAGG-3') and reverse primer SEQ ID NO: 141 (5'-CAACTTCAGCCATCCATTTCTG-3').

[0337] After RNA was subjected to RT-PCR, samples were analyzed using a Caliper instrument using gel capillary electrophoresis. Exon skipping rates were calculated using the following equation: (area under the curve of the skipped band) / (sum of the areas under the curve of the skipped and non-skipped bands)×100.

[0338] Immunohistochemistry: Dystrophin staining: Ten micron frozen tissue sections of mouse quadriceps were used to detect dystrophin with primary dystrophin antibody (dilution 1:250, rabbit, Abcam, catalog no. ab15277) in 10% goat serum + 1% BSA in PBS, and secondary antibody Alexa-Fluoro 488 goat anti-rabbit (dilution 1:1000) in 10% goat serum + 1% BSA.

[0339] Preparation of morpholino subunits [ka] Referring to Scheme 1, B represents a base-pairing moiety, and the morpholino subunit may be prepared from the corresponding ribonucleoside (1) as shown. The morpholino subunit (2) may be optionally protected by reaction with a suitable protecting group precursor, e.g., trityl chloride. The 3' protecting group is generally removed during solid-state oligomer synthesis, as described in more detail below. The base-pairing moiety may be suitably protected for solid-phase oligomer synthesis. Suitable protecting groups include benzoyl for adenine and cytosine, phenylacetyl for guanine, and pivaloyloxymethyl for hypoxanthine (I). The pivaloyloxymethyl group may be introduced at the N1 position of the hypoxanthine heterocyclic base. Although an unprotected hypoxanthine subunit may be used, the yield in the activation reaction is much better when the base is protected. Other suitable protecting groups include those disclosed in U.S. Pat. No. 8,076,476, which is incorporated herein by reference in its entirety.

[0340] Reaction of 3 with an activated phosphorus compound 4 affords a morpholino subunit bearing the desired linkage moiety 5.

[0341] Compounds of structure 4 can be prepared using a variety of methods known to those skilled in the art. Coupling with the morpholino moiety then proceeds as outlined above.

[0342] Compounds of structure 5 can be used in solid phase oligomer synthesis to prepare oligomers containing intersubunit linkages. Such methods are well known in the art. Briefly, compounds of structure 5 can be modified at the 5' end to contain a linker to a solid support. Once supported, the protecting group of 5 (e.g., trityl at the 3' end) is removed and the free amine reacts with an activated phosphorus moiety of a second compound of structure 5. This sequence is repeated until an oligo of the desired length is obtained. The protecting group at the 3' end of the terminal can either be removed or left in place if a 3' modification is desired. The oligo can be removed from the solid support using a variety of methods, or an exemplary treatment with a base to cleave the linkage to the solid support.

[0343] The preparation of morpholino oligomers in general and specific morpholino oligomers of the present disclosure is described in more detail in the Examples.

[0344] Preparation of morpholino oligomers The preparation of compounds of the present disclosure is carried out according to Scheme 2 and using the following protocol.

[0345] [ka] [ka] Preparation of trityl piperazine phenylcarbamate 35: To a cooled suspension of compound 11 in dichloromethane (6 mL / g 11) was added a solution of potassium carbonate (3.2 equiv.) in water (4 mL / g potassium carbonate). To this biphasic mixture was slowly added a solution of phenyl chloroformate (1.03 equiv.) in dichloromethane (2 g / g phenyl chloroformate). The reaction mixture was warmed to 20° C. Upon reaction completion (1-2 h), the layers were separated. The organic layer was washed with water and dried over anhydrous potassium carbonate. The product 35 was isolated by crystallization from acetonitrile.

[0346] Preparation of carbamate alcohol 36: Sodium hydride (1.2 equiv.) was suspended in 1-methyl-2-pyrrolidinone (32 mL / g sodium hydride). To this suspension was added triethylene glycol (10.0 equiv.) and compound 35 (1.0 equiv.). The resulting slurry was heated to 95°C. Upon reaction completion (1-2 h), the mixture was cooled to 20°C. To this mixture was added 30% dichloromethane / methyl tert-butyl ether (v:v) and water. The product-containing organic layer was washed successively with aqueous NaOH, aqueous succinic acid, and saturated aqueous sodium chloride. The product 36 was isolated by crystallization from dichloromethane / methyl tert-butyl ether / heptane.

[0347] Preparation of tere acid 37: To a solution of compound 36 in tetrahydrofuran (7 mL / g 36) was added succinic anhydride (2.0 equiv.) and DMAP (0.5 equiv.). The mixture was heated to 50° C. Upon reaction completion (5 h), the mixture was cooled to 20° C. and adjusted to pH 8.5 with aqueous NaHCO3. Methyl tert-butyl ether was added and the product was extracted into the aqueous layer. Dichloromethane was added and the mixture was adjusted to pH 3 with aqueous citric acid. The product-containing organic layer was washed with a mixture of pH=3 citrate buffer and saturated aqueous sodium chloride. This dichloromethane solution of 37 was used without isolation in the preparation of compound 38.

[0348] Preparation of 38: To a solution of compound 37 was added N-hydroxy-5-norbornene-2,3-dicarboxylic imide (HONB) (1.02 equiv.), 4-dimethylaminopyridine (DMAP) (0.34 equiv.), followed by 1-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) (1.1 equiv.). The mixture was heated to 55 °C. Upon reaction completion (4-5 h), the mixture was cooled to 20 °C and washed successively with 1:1 0.2 M citric acid / brine and brine. The dichloromethane solution underwent solvent exchange into acetone and then N,N-dimethylformamide, and the product was isolated by precipitation from acetone / N,N-dimethylformamide into saturated aqueous sodium chloride. The crude product was reslurried several times in water to remove residual N,N-dimethylformamide and salts.

[0349] PMO synthesis method A: Use of disulfide anchors Introduction of the activated "tail" onto the anchor-loaded resin was carried out in dimethylimidazolidinone (DMI) by the procedure used for incorporation of the subunits during solid-phase synthesis.

[0350] [ka] The procedure was carried out in a silanized jacketed peptide vessel (ChemGlass, NJ, USA) with a coarse porosity (40-60 μm) glass frit, an overhead stirrer, and a Teflon three-way stopcock to allow N2 to be bubbled through the frit or vacuum extraction.

[0351] The resin treatment / wash step in the procedure below consists of two basic operations: resin fluidization or stirred bed reactor and solvent / solution extraction. For resin fluidization, the stopcock was positioned to allow N2 to flow upward through the frit and the specified resin treatment / wash was added to the reactor, permeating and thoroughly wetting the resin. Mixing was then started and the resin slurry was mixed for the specified time. For solvent / solution extraction, mixing and N2 flow were stopped, the vacuum pump was started, and the stopcock was positioned to allow the resin treatment / wash to be drained to waste. All resin treatment / wash volumes were 15 mL / g of resin unless otherwise noted.

[0352] To aminomethyl polystyrene resin (100-200 mesh; approximately 1.0 mmol / g loading based on nitrogen displacement; 75 g, 1 equiv., Polymer Labs, UK, part no. 1464-X799) in a silanized jacketed peptide vessel was added 1-methyl-2-pyrrolidinone (NMP; 20 mL / g resin) and the resin was allowed to swell with mixing for 1-2 h. After draining the swelling solvent, the resin was washed with dichloromethane (2 × 1-2 min), 5% diisopropylethylamine in 25% isopropanol / dichloromethane (2 × 3-4 min), and dichloromethane (2 × 1-2 min). After draining the final wash, the resin was treated with a solution of disulfide anchor 34 in 1-methyl-2-pyrrolidinone (0.17 M; 15 mL / g resin, approximately 2.5 equiv.) and the resin / reagent mixture was heated at 45 °C for 60 h. Upon reaction completion, heating was discontinued, the anchor solution was drained, and the resin was washed with 1-methyl-2-pyrrolidinone (4 × 3-4 min) and dichloromethane (6 × 1-2 min). The resin was treated with a solution of 10% (v / v) diethyl dicarbonate in dichloromethane (16 mL / g, 2 × 5-6 min) and then washed with dichloromethane (6 × 1-2 min). The resin 39 was dried under a stream of N2 for 1-3 h and then under vacuum to constant weight (± 2%). Yield: 110-150% of the original resin weight.

[0353] Determination of Aminomethylpolystyrene-Disulfide Resin Loading: The resin loading (number of potentially available reactive sites) is determined by spectrophotometric assay of the number of triphenylmethyl (trityl) groups per gram of resin.

[0354] Transfer a known weight of dry resin (25 ± 3 mg) to a silanized 25 mL volumetric flask and add approximately 5 mL of 2% (v / v) trifluoroacetic acid in dichloromethane. Mix the contents by gently swirling and allow to stand for 30 min. The volume is brought up to 25 mL with additional 2% (v / v) trifluoroacetic acid in dichloromethane and the contents are mixed thoroughly. Using a positive displacement pipette, transfer an aliquot of the trityl-containing solution (500 μL) to a 10 mL volumetric flask and bring the volume to 10 mL with methanesulfonic acid.

[0355] The trityl cation content in the final solution is measured by UV absorbance at 431.7 nm, and the resin loading is measured in μmol / g trityl groups per gram of resin using the appropriate volume, dilution, extinction coefficient (ε: 41 μmol cm), and resin weight. Assays are performed in triplicate and the average loading is calculated.

[0356] The resin loading procedure of this example provides a loading of approximately 500 μmol / g of resin. When the disulfide anchor incorporation step is performed at room temperature for 24 h, loadings of 300-400 μmol / g were obtained.

[0357] Tail loading: The tail can be introduced to the solid support using the same setup and volumes as for the preparation of the aminomethylpolystyrene-disulfide resin. The anchor-loaded resin was first deprotected under acidic conditions to neutralize the resulting material before coupling. In the coupling step, a solution of 38 (0.2 M) in DMI containing 4-ethylmorpholine (NEM, 0.4 M) was used instead of the disulfide anchor solution. After 2 h at 45 °C, resin 39 was washed twice with 5% diisopropylethylamine in 25% isopropanol / dichloromethane and once with DCM. To the resin was added a solution of benzoic anhydride (0.4 M) and NEM (0.4 M). After 25 min, the reactor jacket was cooled to room temperature and the resin was washed twice with 5% diisopropylethylamine in 25% isopropanol / dichloromethane and eight times with DCM. Resin 40 was filtered and dried under high vacuum. The loading of resin 40 is defined as the loading of the original aminomethylpolystyrene-disulfide resin 39 used in the tail loading.

[0358] Solid Phase Synthesis: Morpholino oligomers were prepared on a Gilson AMS-422 Automated Peptide Synthesizer in a 2 mL Gilson polypropylene reaction column (part number 3980270). An aluminum block with channels for water flow was placed around the column when placed on the synthesizer. Alternatively, the AMS-422 would add reagent / wash solutions, hold for a specified time, and use a vacuum to empty the column.

[0359] For oligomers ranging in length up to about 25 subunits, aminomethylpolystyrene disulfide resins with loadings approaching 500 μmol / g of resin are preferred. For larger oligomers, aminomethylpolystyrene-disulfide resins with loadings of 300-400 μmol / g of resin are preferred. If molecules with 5'-tails are desired, tail-loaded resins are selected with the same loading guidelines.

[0360] The following reagent solutions were prepared: Detritylation solution: 10% cyanoacetic acid (w / v) in 4:1 dichloromethane / acetonitrile Neutralization solution: 5% diisopropylethylamine in 3:1 dichloromethane / isopropanol, and Coupling solution: 0.18 M (or 0.24 M for oligomers grown longer than 20 subunits) activated morpholino subunit of the desired base and linkage type in 1,3-dimethylimidazolidinone, and 0.4 M N ethylmorpholine.

[0361] Dichloromethane (DCM) was used as a transition wash to separate the washes of the different reagent solutions.

[0362] On the synthesizer, with the block set to 42 °C, 2 mL of 1-methyl-2-pyrrolidinone was loaded onto each column containing 30 mg of aminomethyl polystyrene-disulfide resin (or tail resin) and left at room temperature for 30 min. After washing twice with 2 mL of dichloromethane, the following synthesis cycle was used: [Table 25]

[0363] The sequence of individual oligomers was programmed into the synthesizer such that each column received the appropriate coupling solution (A, C, G, T, I) in the appropriate sequence. When an oligomer in a column had completed incorporation of its final subunit, the column was removed from the block and a final cycle was performed manually with a coupling solution consisting of 4-methoxytriphenylmethyl chloride (0.32 M in DMI) containing 0.89 M 4-ethylmorpholine.

[0364] Cleavage from the resin and removal of base and backbone protecting groups: After methoxytritylation, the resin was washed 8 times with 2 mL of 1-methyl-2-pyrrolidinone. 1 mL of cleavage solution consisting of 0.1 M 1,4-dithiothreitol (DTT) and 0.73 M triethylamine in 1-methyl-2-pyrrolidinone was added, the column was capped and left at room temperature for 30 min. It was then drained into a 12 mL Wheaton vial. The heavily shrunken resin was washed twice with 300 μL of cleavage solution. To the solution, 4.0 mL of concentrated aqueous ammonia (stored at -20 °C) was added, the vial was tightly capped (with a screw cap with a Teflon liner) and the mixture was swirled to mix the solution. The vial was placed in a 45 °C oven for 16-24 h, resulting in cleavage of the base and backbone protecting groups.

[0365] Crude product purification: The vial of ammonolysis solution was removed from the oven and allowed to cool to room temperature. The solution was diluted with 20 mL of 0.28% aqueous ammonia and passed through a 2.5 x 10 cm column containing Macroprep HQ resin (BioRad). A salt gradient (A: 0.28% ammonia, B: 1 M sodium chloride in 0.28% ammonia, 0-100% B in 60 min) was used to elute the methoxytrityl-containing peak. The combined fractions were pooled and further processed depending on the desired product.

[0366] Demethoxytritylation of morpholino oligomers: Pooled fractions from Macroprep purification were diluted with 1M H 3 PO 4 to reduce the pH to 2.5. After initial mixing, the sample was left at room temperature for 4 minutes at which time it was neutralized to pH 10-11 with 2.8% ammonia / water. The product was purified by solid phase extraction (SPE).

[0367] SPE column packing and conditioning: Amberchrome CG-300M (Rohm and Haas; Philadelphia, PA) (3 mL) was packed into a 20 mL fritted column (BioRad Econo-Pac Chromatography Columns (732-1011)) and the resin was rinsed with 3 mL of the following: 0.28% NH 4 0.5M NaOH / 80% acetonitrile; 0.5M NaOH / 20% ethanol; water; 50mM H 3 PO 4 / 80% acetonitrile; water; 0.5 NaOH / 20% ethanol; water; 0.28% NH 4 OH.

[0368] SPE purification: The solution from demethoxytritylation was loaded onto the column and the resin was rinsed three times with 3-6 mL of 0.28% aqueous ammonia. A Wheaton vial (12 mL) was placed under the column and the product was eluted by washing twice with 2 mL of 45% acetonitrile in 0.28% aqueous ammonia.

[0369] Product isolation: The solution was frozen in dry ice and the vial was placed in a freeze dryer, resulting in a fluffy white powder. The sample was dissolved in water and filtered using a syringe through a 0.22 micron filter (Pall Life Sciences, Acrodisc 25 mm syringe filter with 0.2 micron HT Tuffryn membrane), the optical density (OD) was measured on a UV spectrophotometer to determine the OD units of oligomers present, and a sample was dispensed for analysis. The solution was then returned to a Wheaton vial for freeze drying.

[0370] Analysis of morpholino oligomers by MALDI: MALDI-TOF mass spectrometry was used to determine the composition of fractions in the purification and to provide evidence of the identity (molecular weight) of the oligomers. Samples were run after dilution using solutions of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapic acid), 3,4,5-trihydroxyacetophenone (THAP), or alpha-cyano-4-hydroxycinnamic acid (HCCA) as matrices. [Table 5-3]

[0371] CPP conjugation (SEQ ID NOs: 136 and 136 disclosed below) [ka] Analytical procedure: Matrix-assisted laser desorption ionization time-of-flight mass spectra (MALDI-TOF-MS) were recorded on a Bruker Autoflex™ Speed ​​using a sinapinic acid (SA) matrix. SCX-HPLC was performed on a Thermo Dionex UltiMate 3000 system equipped with a 3000 diode array detector and a ProPac™ SCX-20 column (250 x 4 mm) using a flow rate of 1.0 mL / min (pH = 2, column temperature 30°C). The mobile phase was A (24 mM H 3 PO 4 A (25% acetonitrile in water containing 1 M KCl and 24 mM H 3 PO 4 25% acetonitrile in water containing 10% acetonitrile). Gradient elution was used: 0 min, 35% B; 2 min, 35% B; 22 min, 80% B; 25 min, 80% B; 25.1 min, 35% B; 30 min, 35% B.

[0372] PMO-A (1.82 g, 0.177 mmol, freshly dried by lyophilization for 2 days, as listed in the table below) [ka] (In the formula, each Nu from 1 to 25 and from 5' to 3' is (SEQ ID NO: 142).) [Table 12]

[0373] To a mixture of Ac-L-Arg-L-Arg-L-Arg-L-Arg-L-Arg-L-Arg-Gly-OH (SEQ ID NO: 136) hexatrifluoroacetate (614.7 mg, 0.354 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexatrifluorophosphate (HATU, 134.4 mg, 0.354 mmol) was added dimethylsulfoxide (DMSO, 20 mL). The mixture was stirred at room temperature for 3 min, and then N,N-diisopropylethylamine (DIPEA, 68.5 mg, 0.530 mmol) was added. After 5 min, the cloudy mixture became a clear solution. The reaction was monitored by SCX-HPLC. After 2 h, 20 mL of 10% ammonium hydroxide solution (2.8% NH 3 ) was added. The mixture was stirred at room temperature for an additional 2 hours. The reaction was quenched by the addition of 400 mL of water. Trifluoroethanol (2.0 mL) was added to the solution.

[0374] The solution was split into two parts, and each part was purified by WCX column (10 g resin per column). Each WCX column was first washed with 20% acetonitrile in water (v / v) to remove the PMO#1 starting material. The washing (225 mL for each column) was stopped when MALDI-TOF mass spectrometry analysis showed the absence of PMO#1 signal. Each column was then washed with water (100 mL per column). The desired product, PPMO#1, was eluted with 2.0 M guanidine HCl (140 mL for each column). The purified solution of PPMO#1 was pooled together and then split into two parts, each desalted by SPE column (10 g resin for each column).

[0375] The SPE columns were first washed with 1.0 M aqueous NaCl (100 mL for each column) to produce the hexahydrochloride salt of PPMO#1. Each SPE column was then washed with water (200 mL for each column). The final desalted PPMO#1 was eluted with 50% acetonitrile in water (v / v, 150 mL for each column). The acetonitrile was removed by evacuation under reduced pressure. The resulting aqueous solution was lyophilized to give the desired conjugate PPMO#1 hexahydrochloride salt (1.93 g, 94.5% yield).

[0376] Example 3: In vitro skipping of exon 53 (RD cells) The PMO compounds targeting human dystrophin (DMD) exon 53 listed in the table below were synthesized according to the methods described above and evaluated for DMD exon 53 skipping in human myoblasts. [Table 13-1] [Table 13-2]

[0377] Specifically, healthy human primary myoblasts were cultured using standard techniques. Lyophilized PMOs were resuspended in nuclease-free water and PMO solutions were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific) to verify molarity. PMOs at 5 μM concentration were delivered to myoblasts using nucleoporation according to the manufacturer's instructions and the P3 kit (Lonza) and incubated at 37 °C, 5% CO prior to RNA extraction. 2 The mixture was incubated overnight in a 37° C. incubator.

[0378] RNA was extracted from PMO or PPMO treated cells using GE Healthcare's RNAspin 96-well RNA isolation kit and subjected to RT-PCR using standard techniques with primers targeting human DMD exons 51 / 52 junction and 54 (forward primer: (SEQ ID NO: 138): CATCAAGCAGAAGGCAACAA, reverse primer: (SEQ ID NO: 139): GAAGTTTCAGGGCCAAGTCA).

[0379] Skipping was measured using a Caliper LabChip bioanalyzer and the % exon skipping (i.e., band intensity of exon-skipped product relative to full-length PCR product) was calculated by the following formula: [Exon 53 skipped product / (sum of exon 53 skipped product and exon 53 non-skipped product)*100]. The results of the exon 53 skipping rate are presented in the table below. [Table 14]

[0380] Example 4: Exon 53 skipping in vitro (myotube cells) Example 4A: 40 μm PPMO PPMO compounds prepared according to the methods described above targeting human dystrophin (DMD) exon 53 as listed in the table below were evaluated for DMD exon 53 skipping in healthy human myotube cells. [Table 15-1] [Table 15-2]

[0381] Specifically, differentiated human primary myotube cells were cultured using standard techniques. Lyophilized PPMOs were resuspended in nuclease-free water, and PPMO solutions were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific) to verify molar concentration. PPMOs were added to myotube cell culture media at 40 μm in SKM-M medium (Zen-Bio, Inc.). After 96 h of incubation, myoblasts were washed with PBS and lysed by RA1 lysis buffer in Illustra GE RNAspin 96 kit (catalog no. 25-055-75, GE Healthcare Bio-Sciences). Total RNA was isolated following the manufacturer's recommendations, except that 40 μL of RNase-free water was used to elute the RNA.

[0382] To determine exon 53 skipping, a two-step end-point RT-PCR was performed. Specifically, 11 microliters of total RNA was first reverse transcribed into cDNA by SuperScript IV First-strand synthesis kit (catalog number 18091200, Invitrogen) using random hexamers according to the manufacturer's instructions. PCR was performed by adding 9 μL of cDNA to Platinum Taq DNA polymerase PCR Supermix High Fidelity (catalog number 12532024, Invitrogen) with primers targeting human DMD exon 51 / 52 junction and 54 (forward primer: (SEQ ID NO: 138): CATCAAGCAGAAGGCAACAA; reverse primer (SEQ ID NO: 139): GAAGTTTCAGGGCCAAGTCA). PCR amplification was performed using a BioRad CFX96 real-time thermocycler using the program shown in the table below. The expression of skipped or non-skipped PCR products was assessed by loading 32 μL of PCR product onto the LabChip GX system using the DNA High Sensitivity Reagent kit (CLS760672, Perkin Elmer). The percentage of DMD exon 53 skipping was calculated as the ratio of the molar concentration (nmol / L) of the exon 53 skipped band (201 bp) compared to the combined molar concentration of the skipped (201 bp) and non-skipped (413 bp) bands. [Table 16]

[0383] The results of the exon 53 skipping rate are presented in the table below. [Table 17]

[0384] Example 4B: Dose response of PPMO at 2.5 μm, 5 μm, 10 μm, and 20 μm PPMO compounds from Example 4A above were evaluated for DMD exon 53 skipping in healthy human myotubes at 2.5 μm, 5 μm, 10 μm, and 20 μm. Specifically, differentiated human primary myotube cells were cultured using standard techniques. Lyophilized PPMOs were resuspended in nuclease-free water, and PPMO solutions were measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific) to verify molar concentrations. PPMOs were added to myotube cell culture media at 2.5 μm, 5 μm, 10 μm, and 20 μm in SKM-M medium (Zen-Bio, Inc.). After 96 hours of incubation, myoblasts were washed with PBS and lysed by RA1 lysis buffer in Illustra GE RNAspin 96 kit (catalog number 25-055-75, GE Healthcare Bio-Sciences). Total RNA was isolated according to the manufacturer's recommendations, except that 40 μL of RNase-free water was used to elute the RNA.

[0385] To determine exon 53 skipping, a two-step end-point RT-PCR was performed. Specifically, 11 microliters of total RNA was first reverse transcribed into cDNA by SuperScript IV First-strand synthesis kit (catalog number 18091200, Invitrogen) using random hexamers according to the manufacturer's instructions. PCR was performed by adding 9 μL of cDNA to Platinum Taq DNA polymerase PCR Supermix High Fidelity (catalog number 12532024, Invitrogen) using primers targeting human DMD exon 51 / 52 junction and 54 (forward primer: (SEQ ID NO: 138): CATCAAGCAGAAGGCAACAA; reverse primer (SEQ ID NO: 139): GAAGTTTCAGGGCCAAGTCA). PCR amplification was performed using a BioRad CFX96 real-time thermocycler using the program shown in the table of Example 4A. The expression of skipped or non-skipped PCR products was assessed by loading 32 μL of PCR product onto the LabChip GX system using the DNA High Sensitivity Reagent kit (CLS760672, Perkin Elmer). The percentage of DMD exon 53 skipping was calculated as the ratio of the molar concentration (nmol / L) of the exon 53 skipped band (201 bp) compared to the combined molar concentration of the skipped (201 bp) and non-skipped (413 bp) bands.

[0386] The results of the exon 53 skipping rate are presented in the table below. [Table 18]

[0387] Example 5: MDX Mouse Study The mdx mouse is a well-characterized animal model of Duchenne muscular dystrophy (DMD), which contains a mutation in exon 23 of the dystrophin gene. The M23D antisense sequence (SEQ ID NO: 137) is known to induce exon 23 skipping and restore functional dystrophin expression. 6-7 week old MDX mice were given a single tail vein injection of either PPMO4225 or PMO4225 from the table below at a dose of 40 mg / kg or with saline. [Table 19]

[0388] Treated mice were sacrificed 7, 30, 60, and 90 days after the single-dose injection (n=6 per group). The diaphragm, heart, and right quadriceps were processed for Western blot analysis to measure dystrophin protein production and RT-PCR analysis to measure the rate of exon skipping, and the left quadriceps was processed for immunohistochemistry and H / E staining as described above.

[0389] Dystrophin protein restoration was quantified by Western blot and the percentage of exon 23 skipping was measured by RT-PCR, respectively, as described above.

[0390] The results of RT-PCR and Western blot are shown in Figure 4A-Figure 9B and the following table. Surprisingly, PPMO4225 induces significantly higher and more sustained levels of dystrophin restoration and exon 23 skipping compared to PMO4225, with the highest level occurring 30 days after injection. Even more surprising, PPMO4225 increased dystrophin levels in the heart, when PMO4225 did not. With PMO4225, dystrophin and exon skipping in the heart were not observed at all time points. [Table 20] [Table 21]

[0391] Immunohistochemistry results are shown in FIG. 10, where PPMO4225 restores dystrophin throughout the quadriceps muscle, whereas 4225 results in a "patchy" pattern of expression. The uniform distribution of dystrophin with PPMO4225 treatment indicates that broad targeting of skeletal muscle is achievable. PPMO4225 has significantly improved delivery over PMO4225 in vivo.

[0392] Example 6: MDX Mouse Dose-Response Study Six- to seven-week-old MDX mice were given a single injection into the tail vein of either PPMO4225 or PMO4225 as described above at doses of 40 mg / kg, 80 mg / kg, or 120 mg / kg (n=6 per group).

[0393] The treated mice were sacrificed 30 days after injection. The diaphragm, quadriceps, and heart were processed for Western blot analysis to measure dystrophin protein production based on the Western blot protocol described above (e.g., used in Example 5) with the following modifications. [Table 22]

[0394] Dystrophin protein restoration as a percentage of wild type is shown in the table below and in Figures 11-16. [Table 23]

[0395] Surprisingly, the data show that a single administration of PPMO4225 dose-dependently increases dystrophin levels in mdx mice to a significantly and substantially greater extent than PMO4225.

[0396] Example 7: MDX Mouse IHC Study of Diaphragm and Heart MDX mice aged 6-7 weeks were given a single tail vein injection of PPMO4225 at a dose of 80 mg / kg or saline, and wild-type mice aged 6-7 weeks were given a single injection of saline. Treated mdx mice, saline mdx mice, and wild-type mice were sacrificed 30 days after the single dose injection (n=4 per group). Immunohistochemistry results are shown in FIG. 17, where the results show a uniform increase in dystrophin in tissues associated with DMD morbidity and mortality in mdx mice treated with PPMO4225. *********************

[0397] All publications and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. References Aartsma-Rus, A., AAJanson, et al. (2004). “Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.” Am J Hum Genet 74(1):83-92. Abes, R., et al. (2008). “Arginine-rich cell penetrating peptides:design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides.” J Pept. Sci. 14:455-460. Alter, J., et al. (2006). “Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.” Nat.Med. 12(2):175-177. Bestas,B.,et al.(2014).“Splice-correcting ligonucleotides restore BTK function in X-linked agammaglobulinemia model.” J Clin Invest. Cirak S.,V.Arechavala-Gomeza,et al.(2011).“Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment:an open-label,phase 2,dose-escalation study.” Lancet 378(9791):595-605. Dunckley,M.G.,I.C.Eperon,et al.(1997).“Modulation of splicing in the DMD gene by antisense oligoribonucleotides.” Nucleosides & Nucleotides 16(7-9):1665-1668. Dunckley,M.G.,M.Manoharan,et al.(1998).“Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.” Hum Mol Genet 7(7):1083-90. Errington,S.J.,C.J.Mann,et al.(2003).“Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.” J Gene Med 5(6):518-27. Goemans,N.M.,M.Tulinius,et al.(2011).“Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy.” N Engl J Med . Jearawiriyapaisarn,N.,H.M.Moulton,et al.(2008).“Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice.” Mol Ther . Jearawiriyapaisarn,N.,et al.(2010).“Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.” Cardiovascular Research 85:444-453. Kinali,M.,V.Arechavala-Gomeza,et al.(2009).“Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy:a single-blind,placebo-controlled,dose-escalation,proof-of-concept study.” Lancet Neurol 8(10):918-28. Leblue,B.,et al.(2008).“Cell penetrating peptide conjugates of steric block oligonucleotides.” Adv. Drug Deliv. Rev. 60:517-529. Lu,Q.L.,C.J.Mann,et al.(2003).“Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.” NatMed 9(8):1009-14. Mann,C.J.,K.Honeyman,et al.(2002).“Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy.” J Gene Med 4(6):644-54. Marshall,N.B.,S.K.Oda,et al.(2007).“Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.” Journal of Immunological Methods 325(1-2):114-126. Matsuo,M.,T.Masumura,et al.(1991).“Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe.” J Clin Invest 87(6):2127-31. McClory,G.,et al.(2006).“Antisense oligonucleotide-induced exon skipping restored dystrophin expression in vitro in a canine model of DMD.” Gene Therapy 13:1373-1381. Monaco,A.P.,C.J.Bertelson,et al.(1988).“An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.” Genomics 2(1):90-5. Moulton,H.M.,(2007).“Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD(Duchenne muscular dystrophy)and inhibit murine coronavirus replication in vivo.” Biochem.Society Trans 35(4):826-828. Pramono,Z.A.,Y.Takeshima,et al.(1996).“Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence.” Biochem Biophys Res Commun 226(2):445-9. Sazani,P.,R.Kole,et al.(2007).Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease. PCT WO2007058894 ,University of North Carolina Sierakowska,H.,M.J.Sambade,et al.(1996).“Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.” Proc Natl Acad Sci USA 93(23):12840-4. Summerton,J.and D.Weller(1997).“Morpholino antisense oligomers:design,preparation,and properties.” Antisense Nucleic Acid Drug Dev 7(3):187-95. Takeshima,Y.,H.Nishio,et al.(1995).“Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe.” J Clin Invest 95(2):515-20. van Deutekom,J.C.,M.Bremmer-Bout,et al.(2001).“Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.” Hum Mol Genet 10(15):1547-54. van Deutekom,J.C.,A.A.Janson,et al.(2007).“Local dystrophin restoration with antisense oligonucleotide PRO051.” N Engl J Med 357(26):2677-86. Wilton,S.D.,A.M.Fall,et al.(2007).“Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript.” Mol Ther 15(7):1288-96. Wilton,S.D.,F.Lloyd,et al.(1999).“Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.” Neuromuscul Disord 9(5):330-8. Wu,B.,H.M.Moulton,et al.(2008).“Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.” Proc Natl Acad Sci USA 105(39):14814-9. Wu,B.,et al.(2012).“Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.” The Am. J. Pathol. 181(2):392-400. Wu,P.,et al.(2007)“Cell-penetrating peptides as transporters for morpholino oligomers:effects of amino acid composition on intracellular delivery and cytotoxicity.” Nucleic Acids Research 35(15):5182-5191. Yin,H.,H.M.Moulton,et al.(2008).“Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.” Hum Mol Genet 17(24):3909-18. Yin, H., et al. (2011). “Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.” Mol.Ther 19(7):1295 - 1303. Youngblood, D., et al. (2006). “Stability of cell-penetrating peptide- morpholino oligomer conjugates in human serum and in cells.” Am.Chem.Soc.

Table 24 - 1

Table 24 - 2

Table 24 - 3

Claims

1. Formula (I): [C76] or a pharma- ceutically acceptable salt thereof, wherein: each Nu is a nucleobase which together form a targeting sequence, T, [C77] is a moiety selected from R 1 But, C 1 ~C 6 is alkyl, An antisense oligomer conjugate, wherein the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA, said exon 53 annealing site being H53D(+22-03).

2. The antisense oligomer conjugate of claim 1 , wherein the targeting sequence is SEQ ID NO:

112.

3. 2. The antisense oligomer conjugate of claim 1, wherein each Nu is independently selected from cytosine (C), guanine (G), thymine (T), adenine (A), 5-methylcytosine (5mC), uracil (U), and hypoxanthine (I).

4. Formula (III): [C78] or a pharma- ceutically acceptable salt thereof, wherein each Nu is a nucleobase that together form a targeting sequence that is complementary to an exon 53 annealing site in a dystrophin pre-mRNA, which is H53D(+22-03).

5. The antisense oligomer conjugate of claim 4 , wherein the targeting sequence is SEQ ID NO:

112.

6. Formula (IV): [C79] or a pharma- ceutically acceptable salt thereof, each Nu is a nucleobase which together form a targeting sequence, T, [C80] is a moiety selected from R 1 But, C 1 ~C 6 is alkyl, R 2 is selected from H or acetyl; An antisense oligomer, wherein the targeting sequence is complementary to an exon 53 annealing site in a dystrophin pre-mRNA that is H53D(+22-03).

7. The targeting sequence is SEQ ID NO: 112, preferably T is [chemical 81] The antisense oligomer of claim 6 ,

8. Formula (V): [chemical 82] or a pharma- ceutically acceptable salt thereof, R is selected from H or acetyl; An antisense oligomer, where each Nu is a nucleobase that together form a targeting sequence that is complementary to an exon 53 annealing site in the dystrophin pre-mRNA, H53D(+22-03).

9. The antisense oligomer of claim 8, wherein the targeting sequence is SEQ ID NO:

112.

10. A pharmaceutical composition comprising the antisense oligomer conjugate of any one of claims 1 to 5, or the antisense oligomer of any one of claims 6 to 9, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

11. 11. A composition comprising the antisense oligomer conjugate of any one of claims 1 to 5, or the antisense oligomer of any one of claims 6 to 9, or the pharmaceutical composition of claim 10, said composition for use in treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, said subject having a mutation in the dystrophin gene that is amenable to exon 53 skipping.

Citation Information

Patent Citations

  • Electrical junction box

    JP2000125448A

  • Resin composition for heat-resistant card

    JP2000256547A

  • Exon-skipping compositions for treating muscular dystrophies

    JP2016521119A

  • oligomers

    US20170204413A1

  • Antisense oligonucleotides which combat aberrant splicing and methods of using the same

    US5627274A